PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17636266-7	2007	Coculture with bone metastatic breast cancer MDA-MB-231 cells had similar effects on the expression of OPG and MCP1 in the osteoblastic cells, and those effects could be partially abolished by the EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	212-220	TNF receptor superfamily member 11b	Homo sapiens	103-106
17636266-7	2007	Coculture with bone metastatic breast cancer MDA-MB-231 cells had similar effects on the expression of OPG and MCP1 in the osteoblastic cells, and those effects could be partially abolished by the EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	212-220	chemokine (C-C motif) ligand 2	Mus musculus	111-115
17636266-7	2007	Coculture with bone metastatic breast cancer MDA-MB-231 cells had similar effects on the expression of OPG and MCP1 in the osteoblastic cells, and those effects could be partially abolished by the EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	212-220	epidermal growth factor receptor	Mus musculus	197-201
17627611-7	2007	The present study showed that whether in vitro or ex vivo the uptake of (11)C-PD153035 closely correlated with EGFR expression levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	78-86	epidermal growth factor receptor	Homo sapiens	111-115
17624262-2	2007	However it is still unclear whether (11)C-PD153035 uptake correlates with EGFR expression levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	42-50	epidermal growth factor receptor	Homo sapiens	74-78
17934341-7	2007	Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	58-66	epidermal growth factor receptor	Homo sapiens	71-75
17934341-7	2007	Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	58-66	tumor necrosis factor	Homo sapiens	116-125
17934341-7	2007	Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	58-66	epidermal growth factor receptor	Homo sapiens	169-173
17934341-7	2007	Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	58-66	tumor necrosis factor	Homo sapiens	190-199
17934341-14	2007	PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	13-17
17934341-14	2007	PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	mitogen-activated protein kinase 1	Homo sapiens	71-74
17934341-14	2007	PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	mitogen-activated protein kinase 1	Homo sapiens	108-111
17934341-14	2007	PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	152-156
17934341-14	2007	PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	aryl hydrocarbon receptor	Homo sapiens	161-164
17533397-6	2007	Parathyroid hormone-related protein gene expression in both lines was reduced 40-80% after treatment with 1 muM of EGFR tyrosine kinase inhibitor PD153035 and precipitating antibodies to AREG.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	146-154	parathyroid hormone like hormone	Homo sapiens	0-35
17533397-6	2007	Parathyroid hormone-related protein gene expression in both lines was reduced 40-80% after treatment with 1 muM of EGFR tyrosine kinase inhibitor PD153035 and precipitating antibodies to AREG.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	146-154	epidermal growth factor receptor	Homo sapiens	115-119
17624262-3	2007	The objective of this study was to investigate the relationship between (11)C-PD153035 accumulation and EGFR expression levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	78-86	epidermal growth factor receptor	Homo sapiens	104-108
17624262-13	2007	CONCLUSIONS: The uptake of PET tracer (11)C-PD153035 closely correlates with the EGFR expression levels in tumor cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	44-52	epidermal growth factor receptor	Homo sapiens	81-85
17286282-0	2007	Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	94-102	retinoic acid receptor beta	Homo sapiens	16-43
17286282-0	2007	Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	94-102	epidermal growth factor receptor	Homo sapiens	51-83
17286282-4	2007	The ErbB-1 inhibitor PD153035 cooperates with retinoic acid during growth inhibition and induces retinoic acid receptor-beta suggesting that ErbB-1 controls retinoic acid receptor-beta.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	21-29	epidermal growth factor receptor	Homo sapiens	4-10
17286282-4	2007	The ErbB-1 inhibitor PD153035 cooperates with retinoic acid during growth inhibition and induces retinoic acid receptor-beta suggesting that ErbB-1 controls retinoic acid receptor-beta.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	21-29	retinoic acid receptor beta	Homo sapiens	97-124
17286282-4	2007	The ErbB-1 inhibitor PD153035 cooperates with retinoic acid during growth inhibition and induces retinoic acid receptor-beta suggesting that ErbB-1 controls retinoic acid receptor-beta.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	21-29	epidermal growth factor receptor	Homo sapiens	4-8
17286282-4	2007	The ErbB-1 inhibitor PD153035 cooperates with retinoic acid during growth inhibition and induces retinoic acid receptor-beta suggesting that ErbB-1 controls retinoic acid receptor-beta.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	21-29	retinoic acid receptor beta	Homo sapiens	157-184
17286282-6	2007	PD153035 inhibits ErbB-1-phosphorylation, whereas its derivative EBE-A22 is inactive.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	18-22
17286282-13	2007	Moreover, PD153035 increases the retinoic acid receptor-beta mRNA half-life.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	10-18	retinoic acid receptor beta	Homo sapiens	33-60
17286282-15	2007	Thus PD153035 induces retinoic acid receptor-beta by ErbB-independent transcriptional and post-transcriptional mechanisms.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	5-13	retinoic acid receptor beta	Homo sapiens	22-49
17286282-15	2007	Thus PD153035 induces retinoic acid receptor-beta by ErbB-independent transcriptional and post-transcriptional mechanisms.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	5-13	epidermal growth factor receptor	Homo sapiens	53-57
17293597-7	2007	When keratinocytes were pretreated with RCR252, an EPCR-blocking antibody, or PD153035, an epidermal growth factor receptor (EGFR) inhibitor, cell proliferation was hindered by more than 30%.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	78-86	epidermal growth factor receptor	Homo sapiens	91-123
17293597-7	2007	When keratinocytes were pretreated with RCR252, an EPCR-blocking antibody, or PD153035, an epidermal growth factor receptor (EGFR) inhibitor, cell proliferation was hindered by more than 30%.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	78-86	epidermal growth factor receptor	Homo sapiens	125-129
17019730-5	2007	Treatment of purified EGFR with PD153035 (PD), an EGFR-specific tyrosine kinase (TK) inhibitor, inhibited the MF-induced EGFR clustering of the purified proteins, an effect also observed for the receptors in cell membrane in the absence of EGF.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Cricetulus griseus	22-26
16837130-4	2007	Our results demonstrated that both EGFR inhibitors inhibited tumor cell growth in a dose-dependent manner, but ANAPD was more potent than PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	138-146	epidermal growth factor receptor	Homo sapiens	35-39
16837130-8	2007	In conclusion, this study demonstrated that both PD153035 and ANAPD inhibit tumor cell growth in HCC through inhibition of EGFR signaling pathway, and ANAPD is a more potent inhibitor than PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	49-57	epidermal growth factor receptor	Homo sapiens	123-127
17019730-5	2007	Treatment of purified EGFR with PD153035 (PD), an EGFR-specific tyrosine kinase (TK) inhibitor, inhibited the MF-induced EGFR clustering of the purified proteins, an effect also observed for the receptors in cell membrane in the absence of EGF.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Cricetulus griseus	50-54
17019730-5	2007	Treatment of purified EGFR with PD153035 (PD), an EGFR-specific tyrosine kinase (TK) inhibitor, inhibited the MF-induced EGFR clustering of the purified proteins, an effect also observed for the receptors in cell membrane in the absence of EGF.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Cricetulus griseus	50-54
17077385-5	2007	We found that its main TER-increasing component is epidermal growth factor (hEGF), as depletion of this peptide with specific antibodies, or inhibition of its receptor with PD153035, abolishes its effect.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	173-181	epidermal growth factor	Homo sapiens	76-80
16964427-8	2006	We also observed that UV radiation induced activation of EGFR in a time- and dose-dependent manner which was inhibited by EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	137-145	epidermal growth factor receptor	Homo sapiens	57-61
17028263-5	2007	Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	91-100	epidermal growth factor receptor	Homo sapiens	14-46
17028263-5	2007	Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	91-100	epidermal growth factor receptor	Homo sapiens	48-52
17028263-5	2007	Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	91-100	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	58-61
17028263-5	2007	Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	91-100	signal transducer and activator of transcription 3	Homo sapiens	152-157
17028263-5	2007	Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	91-100	signal transducer and activator of transcription 3	Homo sapiens	182-187
16848764-6	2006	Furthermore, an EGFR (EGF receptor) kinase inhibitor, PD153035, blocked EGF-induced AQP3 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	epidermal growth factor receptor	Homo sapiens	16-20
16848764-6	2006	Furthermore, an EGFR (EGF receptor) kinase inhibitor, PD153035, blocked EGF-induced AQP3 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	epidermal growth factor receptor	Homo sapiens	22-34
16848764-6	2006	Furthermore, an EGFR (EGF receptor) kinase inhibitor, PD153035, blocked EGF-induced AQP3 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	epidermal growth factor	Homo sapiens	16-19
16848764-6	2006	Furthermore, an EGFR (EGF receptor) kinase inhibitor, PD153035, blocked EGF-induced AQP3 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	aquaporin 3 (Gill blood group)	Homo sapiens	84-88
16956907-7	2007	Inhibition of EGFR by specific inhibitors PD153035 or ZD1839 increased susceptibility to I3C-induced apoptosis of MCF7, MDA-MB-468 and MDA-MB-231 cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	42-50	epidermal growth factor receptor	Homo sapiens	14-18
24557623-11	2007	PD153035, a selective inhibitor of EGFR tyrosine kinase, inhibited the TfR protein expression in UVB-treated cells in a dose-dependent manner (P < 0.05).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	35-39
24557623-11	2007	PD153035, a selective inhibitor of EGFR tyrosine kinase, inhibited the TfR protein expression in UVB-treated cells in a dose-dependent manner (P < 0.05).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	transferrin receptor	Homo sapiens	71-74
17154492-3	2006	The novel molecules were synthesized by combining the structural features of the EGFR inhibitor PD153035 (1) and lipoic acid, which among other therapeutic effects triggers apoptosis in human cancer cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	96-104	epidermal growth factor receptor	Homo sapiens	81-85
16964427-8	2006	We also observed that UV radiation induced activation of EGFR in a time- and dose-dependent manner which was inhibited by EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	137-145	epidermal growth factor receptor	Homo sapiens	122-126
16964427-10	2006	EGFR kinase inhibitor, PD153035, inhibited UV-induced HIF-1alpha and VEGF protein expression in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	23-31	epidermal growth factor receptor	Homo sapiens	0-4
16964427-10	2006	EGFR kinase inhibitor, PD153035, inhibited UV-induced HIF-1alpha and VEGF protein expression in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	23-31	hypoxia inducible factor 1 subunit alpha	Homo sapiens	54-64
16964427-10	2006	EGFR kinase inhibitor, PD153035, inhibited UV-induced HIF-1alpha and VEGF protein expression in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	23-31	vascular endothelial growth factor A	Homo sapiens	69-73
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	123-131	epidermal growth factor receptor	Homo sapiens	69-73
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	123-131	epidermal growth factor receptor	Homo sapiens	107-111
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	123-131	mitogen-activated protein kinase 8	Homo sapiens	178-181
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	123-131	mitogen-activated protein kinase 1	Homo sapiens	186-189
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	123-131	epidermal growth factor receptor	Homo sapiens	107-111
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	123-131	mitogen-activated protein kinase 1	Homo sapiens	250-253
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	237-245	epidermal growth factor receptor	Homo sapiens	69-73
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	237-245	epidermal growth factor receptor	Homo sapiens	107-111
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	237-245	epidermal growth factor receptor	Homo sapiens	107-111
16331686-5	2006	The PGE(2)-induced EGFR phosphorylation and cell invasiveness were blocked by the EP(1) receptor siRNA or antagonist ONO-8711 and by two EGFR tyrosine kinase inhibitors, AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	181-189	epidermal growth factor receptor	Homo sapiens	19-23
16773209-6	2006	TSA transiently activated EGFR tyrosine phosphorylation and AKT activation in a time- and dose-dependent manner, which had been inhibited by EGFR inhibitor PD153035 and PI3 kinase inhibitor LY294002.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	156-164	epidermal growth factor receptor	Homo sapiens	26-30
16773209-6	2006	TSA transiently activated EGFR tyrosine phosphorylation and AKT activation in a time- and dose-dependent manner, which had been inhibited by EGFR inhibitor PD153035 and PI3 kinase inhibitor LY294002.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	156-164	AKT serine/threonine kinase 1	Homo sapiens	60-63
16773209-6	2006	TSA transiently activated EGFR tyrosine phosphorylation and AKT activation in a time- and dose-dependent manner, which had been inhibited by EGFR inhibitor PD153035 and PI3 kinase inhibitor LY294002.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	156-164	epidermal growth factor receptor	Homo sapiens	141-145
16773209-7	2006	We also observed that TSA transiently induced survivin expression that had been inhibited by PD153035 and LY294002, suggesting that TSA-induced survivin expression is mediated by EGFR/PI3 kinase pathway.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	93-101	epidermal growth factor receptor	Homo sapiens	179-183
16410015-5	2006	Zn2+-mediated EGFR phosphorylation did not require ligand binding and was ablated by the EGFR kinase inhibitor PD153035, but not by the Src kinase inhibitor PP2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	111-119	epidermal growth factor receptor	Homo sapiens	14-18
16410015-5	2006	Zn2+-mediated EGFR phosphorylation did not require ligand binding and was ablated by the EGFR kinase inhibitor PD153035, but not by the Src kinase inhibitor PP2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	111-119	epidermal growth factor receptor	Homo sapiens	89-93
16723453-7	2006	PD153035 reduced IL-8, AG1295 repressed IL-6, and both inhibitors partially downregulated VEGF production in UV-exposed PECs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	17-21
16908449-2	2006	Western blotting using phospho-specific antibodies demonstrated that the EGF receptor kinase inhibitor PD153035 decreased both the phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and its upstream signal pathway, including mitogen-activate protein kinase/ERK kinase (MEK)1/2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	103-111	mitogen-activated protein kinase 1	Homo sapiens	150-196
16908449-2	2006	Western blotting using phospho-specific antibodies demonstrated that the EGF receptor kinase inhibitor PD153035 decreased both the phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and its upstream signal pathway, including mitogen-activate protein kinase/ERK kinase (MEK)1/2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	103-111	mitogen-activated protein kinase kinase 1	Homo sapiens	272-291
16443372-8	2006	An ErbB1 tyrosine kinase inhibitor, PD153035, inhibited the TGFalpha effect.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	36-44	epidermal growth factor receptor	Homo sapiens	3-8
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	71-79	epidermal growth factor	Homo sapiens	0-3
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	71-79	matrix metallopeptidase 2	Homo sapiens	12-17
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	71-79	mitogen-activated protein kinase 1	Homo sapiens	154-157
16443372-8	2006	An ErbB1 tyrosine kinase inhibitor, PD153035, inhibited the TGFalpha effect.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	36-44	transforming growth factor alpha	Homo sapiens	60-68
17361080-7	2006	Epidermal growth factor receptor (EGFR) expressed in HaCaT cells was inhibited by PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	epidermal growth factor receptor	Homo sapiens	0-32
17361080-11	2006	Additional treatment of these cells with PD153035 led to a slight decrease in the fraction of PTPIP51-positive cells, which was not statistically significant.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	41-49	regulator of microtubule dynamics 3	Homo sapiens	94-101
16331686-5	2006	The PGE(2)-induced EGFR phosphorylation and cell invasiveness were blocked by the EP(1) receptor siRNA or antagonist ONO-8711 and by two EGFR tyrosine kinase inhibitors, AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	181-189	prostaglandin E receptor 1	Homo sapiens	82-87
16300728-6	2006	Furthermore, the epithelial growth factor (EGF) receptor specific inhibitor (PD153035) reduced vanadate-induced COX-2 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	77-85	epidermal growth factor receptor	Homo sapiens	17-56
16300728-6	2006	Furthermore, the epithelial growth factor (EGF) receptor specific inhibitor (PD153035) reduced vanadate-induced COX-2 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	77-85	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	112-117
17361080-7	2006	Epidermal growth factor receptor (EGFR) expressed in HaCaT cells was inhibited by PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	epidermal growth factor receptor	Homo sapiens	34-38
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	77-85	mitogen-activated protein kinase 1	Homo sapiens	19-22
16039679-6	2006	Consistent with this notion, this action was blocked by the PTKs inhibitor genistein and the EGFR antagonist PD153035, indicating that contraction was, at least in part, attributable to PTKs phosphorylation that activates VR1, resulting in increased intracellular calcium content in the smooth muscle cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	109-117	epidermal growth factor receptor	Cavia porcellus	93-97
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	77-85	AKT serine/threonine kinase 1	Homo sapiens	27-30
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	77-85	epidermal growth factor receptor	Homo sapiens	61-65
16211241-8	2005	Paclitaxel-induced survivin expression was inhibited by the EGFR inhibitor, PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	76-84	epidermal growth factor receptor	Homo sapiens	60-64
15867774-0	2005	The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	73-81	epidermal growth factor receptor	Homo sapiens	14-46
16077934-10	2005	Pretreatment of EGFR inhibitor PD153035 blocked BA-induced EGFR phosphorylation, ERK and AKT activation, and survivin expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	31-39	epidermal growth factor receptor	Homo sapiens	16-20
16077934-10	2005	Pretreatment of EGFR inhibitor PD153035 blocked BA-induced EGFR phosphorylation, ERK and AKT activation, and survivin expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	31-39	epidermal growth factor receptor	Homo sapiens	59-63
16077934-10	2005	Pretreatment of EGFR inhibitor PD153035 blocked BA-induced EGFR phosphorylation, ERK and AKT activation, and survivin expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	31-39	mitogen-activated protein kinase 1	Homo sapiens	81-84
16077934-10	2005	Pretreatment of EGFR inhibitor PD153035 blocked BA-induced EGFR phosphorylation, ERK and AKT activation, and survivin expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	31-39	AKT serine/threonine kinase 1	Homo sapiens	89-92
16117790-3	2005	Surprisingly, an inhibitor of epidermal growth factor receptor tyrosine kinase, PD153035, enhanced the production of CCL17 in HaCaT KC.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	80-88	C-C motif chemokine ligand 17	Homo sapiens	117-122
15952178-6	2005	The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	heparin binding EGF like growth factor	Homo sapiens	14-20
15952178-6	2005	The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	epidermal growth factor receptor	Homo sapiens	59-63
15952178-6	2005	The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	epidermal growth factor receptor	Homo sapiens	64-69
15952178-6	2005	The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	epidermal growth factor receptor	Homo sapiens	117-121
15952178-6	2005	The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	heparin binding EGF like growth factor	Homo sapiens	125-131
16049334-5	2005	The epidermal growth factor receptor inhibitor PD153035 partially blocked the UVB-mediated induction of MMP-1 and totally abrogated its production after stimulation with either heparin-binding epidermal growth factor-like growth factor or epidermal growth factor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	47-55	epidermal growth factor receptor	Homo sapiens	4-36
16049334-5	2005	The epidermal growth factor receptor inhibitor PD153035 partially blocked the UVB-mediated induction of MMP-1 and totally abrogated its production after stimulation with either heparin-binding epidermal growth factor-like growth factor or epidermal growth factor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	47-55	matrix metallopeptidase 1	Homo sapiens	104-109
16207478-5	2005	PD153035, an inhibitor of EGF receptor tyrosine kinase, and PD98059, an inhibitor of Erk, attenuated COX-2 expression in RIE and RIE-RhoA(63L).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	101-106
16207478-5	2005	PD153035, an inhibitor of EGF receptor tyrosine kinase, and PD98059, an inhibitor of Erk, attenuated COX-2 expression in RIE and RIE-RhoA(63L).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	ras homolog family member A	Rattus norvegicus	133-137
15985706-3	2005	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	189-197	LOC100508689	Homo sapiens	133-138
15985706-3	2005	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	189-197	epidermal growth factor receptor	Homo sapiens	166-170
15681694-6	2005	In contrast with block of Src, block of EGFR kinase with PD-153035 (20 nM) inhibited I(Cl,swell).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	57-66	epidermal growth factor receptor	Oryctolagus cuniculus	40-44
15867774-4	2005	The purpose of this study is to evaluate the ability of the epidermal growth factor receptor tyrosine kinase inhibitor PD153035 to abrogate the expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	119-127	epidermal growth factor receptor	Homo sapiens	60-92
15867774-12	2005	CONCLUSIONS: Epidermal growth factor receptor tyrosine kinase inhibitor PD153035 significantly inhibited motility and invasion in malignant pleural mesothelioma cells in vitro, regardless of their epidermal growth factor receptor expression levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	72-80	epidermal growth factor receptor	Homo sapiens	13-45
15766561-7	2005	Western blotting, colorimetric in vitro cell proliferation assays, and reverse transcription-polymerase chain reaction demonstrated that the EGFR inhibitor PD153035 not only blocked activation of EGFR and inhibited cell growth, but also stimulated RAR-beta expression in MDA-MB-468 breast and OVCAR-3 ovarian carcinoma cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	156-164	epidermal growth factor receptor	Homo sapiens	196-200
15766561-7	2005	Western blotting, colorimetric in vitro cell proliferation assays, and reverse transcription-polymerase chain reaction demonstrated that the EGFR inhibitor PD153035 not only blocked activation of EGFR and inhibited cell growth, but also stimulated RAR-beta expression in MDA-MB-468 breast and OVCAR-3 ovarian carcinoma cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	156-164	retinoic acid receptor beta	Homo sapiens	248-256
15766561-10	2005	PD153035-mediated re-induction of RAR-beta was associated with demethylation of the RAR-beta2 gene promoter P2 as demonstrated by methylation-specific polymerase chain reaction.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	retinoic acid receptor beta	Homo sapiens	34-42
15563540-12	2005	ME-induced ERK1/2 phosphorylation was significantly reduced by PD-98059, the EGFR kinase inhibitor PD-153035 (10 microM), and chelerythrine (2 microM).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	99-108	epidermal growth factor receptor	Oryctolagus cuniculus	77-81
15827339-2	2005	We used cDNA microarrays to examine alterations in gene expression after treatment of carcinoma cells with PD153035, a specific and reversible inhibitor of EGFR function.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	107-115	epidermal growth factor receptor	Homo sapiens	156-160
15613483-8	2005	PD153035, a specific inhibitor of tyrosine kinase activity of the EGF receptor, completely blocked PKCalpha translocation induced by EGF.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	protein kinase C alpha	Homo sapiens	99-107
15557365-6	2004	Pretreatment with the EGFR inhibitors AG1478 (5 micromol/L) or PD153035 (1 micromol/L) significantly decreased MT.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	63-71	epidermal growth factor receptor	Mus musculus	22-26
15766561-7	2005	Western blotting, colorimetric in vitro cell proliferation assays, and reverse transcription-polymerase chain reaction demonstrated that the EGFR inhibitor PD153035 not only blocked activation of EGFR and inhibited cell growth, but also stimulated RAR-beta expression in MDA-MB-468 breast and OVCAR-3 ovarian carcinoma cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	156-164	epidermal growth factor receptor	Homo sapiens	141-145
15191553-6	2004	EGF-induced induction of nNOS was completely inhibited by the specific EGFR antagonist PD153035 and by the EGFR and Janus kinase 2/3 inhibitor AG490.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	epidermal growth factor	Homo sapiens	0-3
15304097-6	2004	Inhibition of EGFR with PD153035 impairs the MbetaCD-induced phosphorylation of EGFR, HER2, and ERK, but does not impair the alteration of K14, K10, or involucrin gene expression, indicating that other signaling proteins regulate this phenomenon.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	24-32	epidermal growth factor receptor	Homo sapiens	14-18
15304097-6	2004	Inhibition of EGFR with PD153035 impairs the MbetaCD-induced phosphorylation of EGFR, HER2, and ERK, but does not impair the alteration of K14, K10, or involucrin gene expression, indicating that other signaling proteins regulate this phenomenon.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	24-32	epidermal growth factor receptor	Homo sapiens	80-84
15304097-6	2004	Inhibition of EGFR with PD153035 impairs the MbetaCD-induced phosphorylation of EGFR, HER2, and ERK, but does not impair the alteration of K14, K10, or involucrin gene expression, indicating that other signaling proteins regulate this phenomenon.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	24-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
15304097-6	2004	Inhibition of EGFR with PD153035 impairs the MbetaCD-induced phosphorylation of EGFR, HER2, and ERK, but does not impair the alteration of K14, K10, or involucrin gene expression, indicating that other signaling proteins regulate this phenomenon.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	24-32	mitogen-activated protein kinase 1	Homo sapiens	96-99
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	135-143	epidermal growth factor receptor	Homo sapiens	30-34
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	135-143	mitogen-activated protein kinase 1	Homo sapiens	35-38
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	135-143	AKT serine/threonine kinase 1	Homo sapiens	39-42
15562758-2	2004	METHODS: The inhibitor of EGFR, PD153035, was used to block the signal transduction of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Homo sapiens	26-30
15562758-2	2004	METHODS: The inhibitor of EGFR, PD153035, was used to block the signal transduction of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Homo sapiens	87-91
15562758-6	2004	The phosphatation of STAT3 induced by HB-EGF but not by IL-6 was blocked by PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	76-84	signal transducer and activator of transcription 3	Homo sapiens	21-26
15562758-6	2004	The phosphatation of STAT3 induced by HB-EGF but not by IL-6 was blocked by PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	76-84	heparin binding EGF like growth factor	Homo sapiens	38-44
15562758-7	2004	CONCLUSION: The proliferation and survival of myeloma cells may be suppressed by PD153035 due to the blockage of phosphatation of STAT3 induced by the activation of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	81-89	signal transducer and activator of transcription 3	Homo sapiens	130-135
15562758-7	2004	CONCLUSION: The proliferation and survival of myeloma cells may be suppressed by PD153035 due to the blockage of phosphatation of STAT3 induced by the activation of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	81-89	epidermal growth factor receptor	Homo sapiens	165-169
15381832-3	2004	Using [14C]choline-labeled gastric mucosal cells in culture, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on phospholipid release was subject to a dose-dependent suppression by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	230-238	epidermal growth factor receptor	Homo sapiens	207-211
15191553-6	2004	EGF-induced induction of nNOS was completely inhibited by the specific EGFR antagonist PD153035 and by the EGFR and Janus kinase 2/3 inhibitor AG490.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	nitric oxide synthase 1	Homo sapiens	25-29
15191553-6	2004	EGF-induced induction of nNOS was completely inhibited by the specific EGFR antagonist PD153035 and by the EGFR and Janus kinase 2/3 inhibitor AG490.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	epidermal growth factor receptor	Homo sapiens	71-75
15110780-3	2004	Using sublingual gland acinar cells, we show that prosecretory effect of isoproterenol on phospholipid release was subjected to suppression by EGFR kinase inhibitor, PD153035, and wortmannin, an inhibitor of PI3K, but not by PD98059, an inhibitor of extracellular signal regulated kinase (ERK).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	166-174	mitogen-activated protein kinase 1	Homo sapiens	289-292
15527548-3	2004	Using [(3)H]glucosamine-labeled mucous acinar cells of sublingual salivary gland in culture, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited in a concentration-dependent manner by EGFR kinase inhibitor, PD153035, as well as wortmannin, an inhibitor of PI3K.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	263-271	LOC100508689	Homo sapiens	171-176
15054105-6	2004	The use of a specific EGFR tyrosine kinase inhibitor, PD153035, correlated with PPARgamma dephosphorylation and translocation to the nucleus, indicating a mechanism for regulating the balance between proliferation and differentiation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	epidermal growth factor receptor	Homo sapiens	22-26
15054105-6	2004	The use of a specific EGFR tyrosine kinase inhibitor, PD153035, correlated with PPARgamma dephosphorylation and translocation to the nucleus, indicating a mechanism for regulating the balance between proliferation and differentiation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	peroxisome proliferator activated receptor gamma	Homo sapiens	80-89
15070968-7	2004	When EGF receptor (EGFR) kinase activity was blocked using PD153035, high passage IGFBP-3 transfectants were growth inhibited compared with controls treated with inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	59-67	epidermal growth factor receptor	Homo sapiens	5-17
15070968-7	2004	When EGF receptor (EGFR) kinase activity was blocked using PD153035, high passage IGFBP-3 transfectants were growth inhibited compared with controls treated with inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	59-67	epidermal growth factor receptor	Homo sapiens	19-23
15070968-7	2004	When EGF receptor (EGFR) kinase activity was blocked using PD153035, high passage IGFBP-3 transfectants were growth inhibited compared with controls treated with inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	59-67	insulin like growth factor binding protein 3	Homo sapiens	82-89
15072578-6	2004	Treatment of keratinocytes with a specific erbB1 inhibitor (PD153035) reduced PTHrP mRNA levels by >80% in rapidly growing keratinocytes.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	60-68	parathyroid hormone like hormone	Homo sapiens	78-83
14704150-10	2004	OPN-induced ERK phosphorylation, AP-1 activation, uPA secretion, and cell motility were suppressed when cells were transfected with dn c-Src or pretreated with alpha(v)beta(3) integrin antibody, c-Src kinase inhibitor (pp2), EGFR tyrosine kinase inhibitor (PD153035), and MEK-1 inhibitor (PD98059).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	257-265	secreted phosphoprotein 1	Homo sapiens	0-3
14704150-10	2004	OPN-induced ERK phosphorylation, AP-1 activation, uPA secretion, and cell motility were suppressed when cells were transfected with dn c-Src or pretreated with alpha(v)beta(3) integrin antibody, c-Src kinase inhibitor (pp2), EGFR tyrosine kinase inhibitor (PD153035), and MEK-1 inhibitor (PD98059).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	257-265	mitogen-activated protein kinase 1	Homo sapiens	12-15
14704150-10	2004	OPN-induced ERK phosphorylation, AP-1 activation, uPA secretion, and cell motility were suppressed when cells were transfected with dn c-Src or pretreated with alpha(v)beta(3) integrin antibody, c-Src kinase inhibitor (pp2), EGFR tyrosine kinase inhibitor (PD153035), and MEK-1 inhibitor (PD98059).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	257-265	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	135-140
15110780-3	2004	Using sublingual gland acinar cells, we show that prosecretory effect of isoproterenol on phospholipid release was subjected to suppression by EGFR kinase inhibitor, PD153035, and wortmannin, an inhibitor of PI3K, but not by PD98059, an inhibitor of extracellular signal regulated kinase (ERK).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	166-174	mitogen-activated protein kinase 1	Homo sapiens	250-287
14996711-3	2004	Here, we report a protective effect of the EGFR inhibitors AG1478 and PD153035 against cell death induced by acute hypoxia, which contrasts with their proapoptotic effects under normoxia.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	70-78	epidermal growth factor receptor	Homo sapiens	43-47
15009100-8	2004	The epidermal growth factor receptor-specific tyrosine kinase inhibitor PD153035 abrogated anthralin-induced epidermal growth factor receptor phosphorylation and activation of extracellular-regulated kinase 1/2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	72-80	epidermal growth factor receptor	Homo sapiens	4-36
15009100-8	2004	The epidermal growth factor receptor-specific tyrosine kinase inhibitor PD153035 abrogated anthralin-induced epidermal growth factor receptor phosphorylation and activation of extracellular-regulated kinase 1/2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	72-80	epidermal growth factor receptor	Homo sapiens	109-141
14984009-4	2003	Ethanol stimulated MAPK activity was blocked by the protein kinase C (PKC) inhibitor (GF109203X) and epidermal growth factor (EGF) receptor antagonist (PD153035) by 41 +/- 24 and 34 +/- 12.3%, respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	152-160	epidermal growth factor receptor	Rattus norvegicus	101-139
12966092-5	2003	The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	73-81	epidermal growth factor receptor	Homo sapiens	14-46
12966092-5	2003	The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	73-81	epidermal growth factor receptor	Homo sapiens	48-52
12966092-5	2003	The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	73-81	peroxisome proliferator activated receptor alpha	Homo sapiens	113-122
12966092-5	2003	The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	73-81	mitogen-activated protein kinase 1	Homo sapiens	151-154
12794766-1	2003	Our results revealed that the blockade of epidermal growth factor receptor (EGFR) tyrosine kinase and protein kinase A (PKA) signaling pathways by specific inhibitors (PD153035 and Rp-cAMPs) leads to a synergistic inhibition of EGF- and serum-stimulated growth of human prostatic cancer cells (LNCaP, DU145 and PC3) concomitant with an arrest in the G1 phase of cellular cycle.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	epidermal growth factor receptor	Homo sapiens	42-74
12943688-3	2003	Heregulin beta1, a ligand of ErbB receptors, enhanced the generation of Nkx2.5/GFP(+) cardiomyocytes in embryoid bodies, while AG1478 and PD153035, inhibitors of ErbBs, drastically blocked the generation of Nkx2.5/GFP(+) cardiomyocytes.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	138-146	epidermal growth factor receptor	Homo sapiens	29-33
14500405-6	2003	In the presence of EGFR-specific tyrosine kinase inhibitor (PD153035) or an anti-EGFR antibody (C225), PLCgamma-1 activation was abrogated indicating that PLCgamma-1 was downstream of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	60-68	epidermal growth factor receptor	Homo sapiens	19-23
14500405-6	2003	In the presence of EGFR-specific tyrosine kinase inhibitor (PD153035) or an anti-EGFR antibody (C225), PLCgamma-1 activation was abrogated indicating that PLCgamma-1 was downstream of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	60-68	phospholipase C gamma 1	Homo sapiens	103-113
14500405-6	2003	In the presence of EGFR-specific tyrosine kinase inhibitor (PD153035) or an anti-EGFR antibody (C225), PLCgamma-1 activation was abrogated indicating that PLCgamma-1 was downstream of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	60-68	phospholipase C gamma 1	Homo sapiens	155-165
12915106-7	2003	The EGFR kinase inhibitor PD153035 ablated all phosphorylation induced by EGF but none caused by Zn(2+).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	26-34	epidermal growth factor receptor	Homo sapiens	4-8
12915106-8	2003	PD153035 abolished EGF-induced phosphorylation of the EGFR substrate Cbl, but had no effect on levels of phospho-Cbl caused by Zn(2+).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	54-58
12915106-8	2003	PD153035 abolished EGF-induced phosphorylation of the EGFR substrate Cbl, but had no effect on levels of phospho-Cbl caused by Zn(2+).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	Cbl proto-oncogene	Homo sapiens	69-72
14612544-5	2003	Treatment of our in vitro glioma model with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resulted in significant suppression of EGFR autophosphorylation even with very low levels of drug.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	90-98	epidermal growth factor receptor	Homo sapiens	48-52
14612544-5	2003	Treatment of our in vitro glioma model with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resulted in significant suppression of EGFR autophosphorylation even with very low levels of drug.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	90-98	epidermal growth factor receptor	Homo sapiens	156-160
14612544-5	2003	Treatment of our in vitro glioma model with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resulted in significant suppression of EGFR autophosphorylation even with very low levels of drug.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	90-98	epidermal growth factor receptor	Homo sapiens	156-160
12876202-9	2003	We demonstrate the future potential of this approach by characterizing the action of the epidermal growth factor receptor inhibitor PD153035 on cells by using Ab arrays; direct scale-up to array-based screening in 96- and 384-well plates should allow small molecules to be identified with specific inhibitory profiles against a signaling network.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	epidermal growth factor receptor	Homo sapiens	89-121
12672650-6	2003	The TGF-alpha induction of AP-1 transcriptional activity in gastric mucosal cells from aged rats could be totally abrogated by either PD153035, a specific inhibitor of EGFR tyrosine kinase, or PD98059, a specific inhibitor of MEKs, but not by Wortmannin, which inhibits phosphatidylinositol kinase.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	134-142	transforming growth factor alpha	Rattus norvegicus	4-13
12672650-6	2003	The TGF-alpha induction of AP-1 transcriptional activity in gastric mucosal cells from aged rats could be totally abrogated by either PD153035, a specific inhibitor of EGFR tyrosine kinase, or PD98059, a specific inhibitor of MEKs, but not by Wortmannin, which inhibits phosphatidylinositol kinase.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	134-142	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-31
12672650-6	2003	The TGF-alpha induction of AP-1 transcriptional activity in gastric mucosal cells from aged rats could be totally abrogated by either PD153035, a specific inhibitor of EGFR tyrosine kinase, or PD98059, a specific inhibitor of MEKs, but not by Wortmannin, which inhibits phosphatidylinositol kinase.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	134-142	epidermal growth factor receptor	Rattus norvegicus	168-172
12794766-1	2003	Our results revealed that the blockade of epidermal growth factor receptor (EGFR) tyrosine kinase and protein kinase A (PKA) signaling pathways by specific inhibitors (PD153035 and Rp-cAMPs) leads to a synergistic inhibition of EGF- and serum-stimulated growth of human prostatic cancer cells (LNCaP, DU145 and PC3) concomitant with an arrest in the G1 phase of cellular cycle.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	epidermal growth factor receptor	Homo sapiens	76-80
12794766-1	2003	Our results revealed that the blockade of epidermal growth factor receptor (EGFR) tyrosine kinase and protein kinase A (PKA) signaling pathways by specific inhibitors (PD153035 and Rp-cAMPs) leads to a synergistic inhibition of EGF- and serum-stimulated growth of human prostatic cancer cells (LNCaP, DU145 and PC3) concomitant with an arrest in the G1 phase of cellular cycle.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	chromobox 8	Homo sapiens	311-314
12794766-3	2003	Moreover, we observed that the inhibition of acidic sphingomyelinase and caspase cascades results in a marked reduction of DNA fragmentation and apoptotic death induced by PD153035, alone or in combination with Rp-cAMPs, in EGF stimulated PC3 cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	172-180	chromobox 8	Homo sapiens	239-242
12794766-6	2003	Additionally, the cellular ceramide content estimated for PC3 cells was increased after treatment with PD153035, alone or in combination, at a lower dose with OE and Rp-cAMPs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	103-111	chromobox 8	Homo sapiens	58-61
12794766-7	2003	The synergistic apoptotic effect of PD153035 plus Rp-cAMPs induced in PC3 was also accompanied by a significant rate of mitochondrial membrane depolarization and release of cytochrome c into cytosol as compared to drugs alone.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	36-44	chromobox 8	Homo sapiens	70-73
12794766-7	2003	The synergistic apoptotic effect of PD153035 plus Rp-cAMPs induced in PC3 was also accompanied by a significant rate of mitochondrial membrane depolarization and release of cytochrome c into cytosol as compared to drugs alone.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	36-44	cytochrome c, somatic	Homo sapiens	173-185
12466022-4	2003	Pharmacological inhibition of EGF receptor kinase activity with AG1478 or PD153035 blocked urea-inducible transcription and expression of the immediate-early gene, Egr-1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor receptor	Mus musculus	30-42
12733059-10	2003	Potent specific EGFR inhibitors, such as PD153035 and Tyrphostin 25, as well as Calphostin C, an inhibitor of PKC, significantly blocked the effect of TPA on AJs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	41-49	epidermal growth factor receptor	Homo sapiens	16-20
12594213-3	2003	The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	249-257	epidermal growth factor receptor	Homo sapiens	34-66
12594213-3	2003	The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	249-257	epidermal growth factor receptor	Homo sapiens	68-72
12594213-3	2003	The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	249-257	epidermal growth factor receptor	Homo sapiens	114-118
12594213-3	2003	The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	249-257	epidermal growth factor receptor	Homo sapiens	114-118
12466022-4	2003	Pharmacological inhibition of EGF receptor kinase activity with AG1478 or PD153035 blocked urea-inducible transcription and expression of the immediate-early gene, Egr-1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	jun proto-oncogene	Mus musculus	142-157
12466022-4	2003	Pharmacological inhibition of EGF receptor kinase activity with AG1478 or PD153035 blocked urea-inducible transcription and expression of the immediate-early gene, Egr-1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	early growth response 1	Mus musculus	164-169
12223343-3	2002	Both Cdx2 and HB-EGF stimulated cell proliferation and migration, and their effects were inhibited partially by an EGF receptor-specific tyrosine kinase inhibitor, PD-153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	164-173	caudal type homeo box 2	Rattus norvegicus	5-9
12223343-3	2002	Both Cdx2 and HB-EGF stimulated cell proliferation and migration, and their effects were inhibited partially by an EGF receptor-specific tyrosine kinase inhibitor, PD-153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	164-173	heparin-binding EGF-like growth factor	Rattus norvegicus	14-20
11943669-4	2002	Each metal significantly increased Ras activity, and this effect was inhibited by the EGFR tyrosine kinase activity inhibitor PD-153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	126-135	epidermal growth factor receptor	Homo sapiens	86-90
12171571-2	2002	PD-153035, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, is an ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFr), with no appreciable inhibitory activity against several other kinases.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-9	epidermal growth factor receptor	Homo sapiens	145-149
12171571-2	2002	PD-153035, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, is an ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFr), with no appreciable inhibitory activity against several other kinases.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	11-54	epidermal growth factor receptor	Homo sapiens	145-149
11992543-7	2002	EGFR antagonist PD153035 and anti-EGFR antibody C225 completely inhibited EGF-induced reporter activity and cytokine expression, but only partially inhibited constitutive activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	16-24	epidermal growth factor receptor	Homo sapiens	0-4
11792073-8	2002	Intravascular administration of human EGF increased Ppa, and pretreatment with PD153035, an EGF receptor-specific tyrosine kinase inhibitor, attenuated ROFA-induced pulmonary vasoconstriction.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	79-87	epidermal growth factor receptor	Homo sapiens	92-104
11943650-7	2002	Pertussis toxin and two specific epidermal growth factor receptor (EGFR) inhibitors (AG-1478 and PD-153035) prevented the stretch-induced ERK1/2 activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	97-106	epidermal growth factor receptor	Homo sapiens	33-65
11943650-7	2002	Pertussis toxin and two specific epidermal growth factor receptor (EGFR) inhibitors (AG-1478 and PD-153035) prevented the stretch-induced ERK1/2 activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	97-106	epidermal growth factor receptor	Homo sapiens	67-71
11943650-7	2002	Pertussis toxin and two specific epidermal growth factor receptor (EGFR) inhibitors (AG-1478 and PD-153035) prevented the stretch-induced ERK1/2 activation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	97-106	mitogen-activated protein kinase 3	Homo sapiens	138-144
11592962-4	2001	We demonstrated that potent inhibitors of the EGFR, PD153035 and AG1478, blocked TPA-induced phosphorylation of extracellular signal-regulated kinases (ERKs), AP-1 activity, and cell transformation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	52-60	mitogen-activated protein kinase 1	Homo sapiens	152-156
11179516-12	2001	EGF receptor kinase inhibitor PD153035 and AG1478 and MEK inhibitor PD98059 also blocked IL-1 beta induction of MMP-1 in cultured human keratinocytes.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	interleukin 1 beta	Homo sapiens	89-98
11879570-4	2001	Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	219-227	epidermal growth factor receptor	Homo sapiens	167-171
11479217-1	2001	Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	154-163	epidermal growth factor receptor	Rattus norvegicus	22-34
11479217-1	2001	Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	154-163	epidermal growth factor receptor	Rattus norvegicus	36-40
11431328-2	2001	Although the EGFR-specific antagonist PD153035 increased caspase-3 activity, this was independent of FAK activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	38-46	epidermal growth factor receptor	Homo sapiens	13-17
11431328-2	2001	Although the EGFR-specific antagonist PD153035 increased caspase-3 activity, this was independent of FAK activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	38-46	caspase 3	Homo sapiens	57-66
11179516-8	2001	EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	epidermal growth factor receptor	Homo sapiens	0-12
11179516-8	2001	EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	interleukin 1 beta	Homo sapiens	60-69
11179516-8	2001	EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	epidermal growth factor receptor	Homo sapiens	78-90
11179516-10	2001	We found that IL-1 beta-induced ERK phosphorylation, PD153035 and MEK inhibitor PD98059 blocked IL-1 beta-induced ERK activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	53-61	interleukin 1 beta	Homo sapiens	14-23
11179516-10	2001	We found that IL-1 beta-induced ERK phosphorylation, PD153035 and MEK inhibitor PD98059 blocked IL-1 beta-induced ERK activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	53-61	interleukin 1 beta	Homo sapiens	96-105
11879570-4	2001	Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	219-227	ubiquitin associated and SH3 domain containing B	Homo sapiens	60-63
11879570-4	2001	Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	219-227	ribosomal protein S6 kinase B1	Homo sapiens	64-67
11879570-4	2001	Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	219-227	cellular inhibitor of PP2A	Homo sapiens	69-72
11879570-4	2001	Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	219-227	ribosomal protein S6 kinase A2	Homo sapiens	73-76
11717368-5	2001	Treatment with purified L-EGF substantially enhanced axonal regeneration of all three types of neurons, an effect inhibited by submicromolar doses of PD153035, a specific EGF receptor (EGFR) tyrosine kinase inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	150-158	epidermal growth factor	Homo sapiens	26-29
11717368-5	2001	Treatment with purified L-EGF substantially enhanced axonal regeneration of all three types of neurons, an effect inhibited by submicromolar doses of PD153035, a specific EGF receptor (EGFR) tyrosine kinase inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	150-158	epidermal growth factor	Homo sapiens	171-174
11717368-6	2001	In addition, PD153035 and K252a, a nonspecific kinase inhibitor, also reduced the degree of axonal regeneration that occurs without L-EGF supplementation, indicating that L-EGF or other EGFR ligands synthesized in the CNS participate in the regenerative response.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	13-21	epidermal growth factor	Homo sapiens	173-176
11822173-1	2001	The 4-anilinoquinazoline PD 153035 (1) is a potential antitumor agent which acts by inhibiting tyrosine kinase activity of epidermal growth factor receptor (EFGR) via competitive binding at the ATP site of enzyme.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	25-34	epidermal growth factor receptor	Homo sapiens	123-155
11562388-5	2001	In some experiments, EGFR kinase activity in parental cells was inhibited by treatment with PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	92-100	epidermal growth factor receptor	Homo sapiens	21-25
11179516-12	2001	EGF receptor kinase inhibitor PD153035 and AG1478 and MEK inhibitor PD98059 also blocked IL-1 beta induction of MMP-1 in cultured human keratinocytes.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	matrix metallopeptidase 1	Homo sapiens	112-117
11178955-2	2001	AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	11-19	epidermal growth factor receptor	Homo sapiens	72-77
11178955-2	2001	AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	11-19	epidermal growth factor receptor	Homo sapiens	125-130
11178955-2	2001	AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	11-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-151
10962438-5	2000	The anti-EGFR monoclonal antibody (MAb) 225 and the EGFR tyrosine kinase inhibitor PD153035 blocked anchorage-independent growth of Ha-ras transformed cells in soft agar and were more effective when used in combination.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	83-91	epidermal growth factor receptor	Homo sapiens	52-56
11169465-6	2001	Surprisingly, inhibition of the TGFalpha receptors" tyrosine kinase activity with nanomolar concentrations of PD153035 increased the accumulation of differentiated characteristics in the presence or absence of ligand.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	110-118	transforming growth factor alpha	Gallus gallus	32-40
11169465-12	2001	PD153035 reduced, but did not eliminate, ERK2 phosphorylation in response to TGFalpha.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	transforming growth factor alpha	Gallus gallus	77-85
11257459-6	2001	In all cases, EGFR tyrosine phosphorylation was completely inhibited by pretreatment of PD153035 (100 nM, 1 h).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	88-96	epidermal growth factor receptor	Homo sapiens	14-18
11257459-8	2001	In both UV and EGF cases, the phosphorylation of IRAK was inhibited by pretreatment of PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	interleukin 1 receptor associated kinase 1	Homo sapiens	49-53
11257459-10	2001	In vitro kinase assay using GST-c-Jun as a substrate revealed that pretreatment of PD153035 completely inhibited UV- and IL-1-induced c-Jun kinase activity in cultured keratinocytes.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	83-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-37
11257459-10	2001	In vitro kinase assay using GST-c-Jun as a substrate revealed that pretreatment of PD153035 completely inhibited UV- and IL-1-induced c-Jun kinase activity in cultured keratinocytes.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	83-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	134-139
11169460-2	2001	The anti-EGF receptor (EGFR) blocking monoclonal antibody (MAb) 225 and the EGFR tyrosine kinase inhibitor PD153035 were able to inhibit the induction of HB-EGF mRNA levels in MCF-10A cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	107-115	heparin binding EGF like growth factor	Homo sapiens	154-160
11169460-3	2001	However, the Ha-ras transformed MCF-10A cells were more refractory to inhibition by these agents and only a combination of the 225 MAb and PD153035 was able to significantly abrogate HB-EGF induction by EGF.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	139-147	heparin binding EGF like growth factor	Homo sapiens	183-189
10970776-4	2000	The Src-family tyrosine kinase inhibitor PP1, as well as specific inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR TK) by PD153035, also blocks PYY stimulation of MAPK.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	146-154	epidermal growth factor receptor	Homo sapiens	84-116
10970776-4	2000	The Src-family tyrosine kinase inhibitor PP1, as well as specific inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR TK) by PD153035, also blocks PYY stimulation of MAPK.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	146-154	epidermal growth factor receptor	Homo sapiens	134-138
10970776-4	2000	The Src-family tyrosine kinase inhibitor PP1, as well as specific inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR TK) by PD153035, also blocks PYY stimulation of MAPK.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	146-154	peptide YY	Homo sapiens	168-171
10416822-1	1999	The biodistribution of 11C-labeled 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, an inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase, has been evaluated in vivo in rats using positron emission tomography (PET).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	35-78	epidermal growth factor receptor	Rattus norvegicus	100-138
10911738-3	2000	The specific EGFR inhibitor PD153035 markedly decreased UVB-induced phosphorylation of EGFR, ERK1/2 and shc, whereas p38 activation was unaffected.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	epidermal growth factor receptor	Homo sapiens	13-17
10911738-3	2000	The specific EGFR inhibitor PD153035 markedly decreased UVB-induced phosphorylation of EGFR, ERK1/2 and shc, whereas p38 activation was unaffected.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	epidermal growth factor receptor	Homo sapiens	87-91
10911738-3	2000	The specific EGFR inhibitor PD153035 markedly decreased UVB-induced phosphorylation of EGFR, ERK1/2 and shc, whereas p38 activation was unaffected.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	mitogen-activated protein kinase 3	Homo sapiens	93-99
10911738-3	2000	The specific EGFR inhibitor PD153035 markedly decreased UVB-induced phosphorylation of EGFR, ERK1/2 and shc, whereas p38 activation was unaffected.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	SHC adaptor protein 1	Homo sapiens	104-107
10601294-5	1999	These effects were attenuated by EGFR tyrosine kinase inhibitor PD153035 or an anti-EGFR monoclonal antibody, whereas protein kinase C inhibitors H7 and bisindolylmaleimide I or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 abolished profilaggrin up-regulation but not K10 suppression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	64-72	epidermal growth factor receptor	Homo sapiens	33-37
10601294-5	1999	These effects were attenuated by EGFR tyrosine kinase inhibitor PD153035 or an anti-EGFR monoclonal antibody, whereas protein kinase C inhibitors H7 and bisindolylmaleimide I or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 abolished profilaggrin up-regulation but not K10 suppression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	64-72	keratin 10	Homo sapiens	319-322
10564177-7	1999	Furthermore, the EGF receptor-specific tyrosine kinase inhibitor (PD-153035) significantly blocked the phosphorylation of MEK1/2 initiated by metals.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	66-75	epidermal growth factor receptor	Homo sapiens	17-29
10564177-7	1999	Furthermore, the EGF receptor-specific tyrosine kinase inhibitor (PD-153035) significantly blocked the phosphorylation of MEK1/2 initiated by metals.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	66-75	mitogen-activated protein kinase kinase 1	Homo sapiens	122-128
10473113-9	1999	PD153035 reduced invasiveness to levels similar to those seen with U73122, suggesting that the autocrine EGFR stimulatory loop is functioning to promote invasiveness.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	105-109
10318765-10	1999	The EGF-induced increase in the erbB2 cluster size was inhibited by the EGFR-specific tyrosine kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	112-120	epidermal growth factor	Homo sapiens	4-7
10318765-10	1999	The EGF-induced increase in the erbB2 cluster size was inhibited by the EGFR-specific tyrosine kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	112-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-37
10318765-10	1999	The EGF-induced increase in the erbB2 cluster size was inhibited by the EGFR-specific tyrosine kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	112-120	epidermal growth factor receptor	Homo sapiens	72-76
10621850-4	1999	We tested the in vitro therapeutic efficacy of PD153035--a potent, specific inhibitor of the tyrosine kinase intrinsic to the EGF receptor--by employing a well-characterized cell line derived from human gingival SCCHN.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	47-55	epidermal growth factor receptor	Homo sapiens	126-138
10621850-6	1999	PD153035, at nanomolar concentrations, inhibited autophosphorylation of the EGF receptor induced by EGF stimulation and the inhibition occurred in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	76-88
10583160-4	1999	SU5271 potently inhibits ligand-induced autophosphorylation of EGFR, and downstream signal transduction events, including DNA replication and cell cycle progression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-6	epidermal growth factor receptor	Homo sapiens	63-67
10583160-5	1999	SU5271, at micromolar concentrations, inhibited the proliferation of keratinocytes isolated from psoriatic lesions in excellent correlation with its EGFR kinase inhibitory activity in these cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-6	epidermal growth factor receptor	Homo sapiens	149-153
9774435-5	1998	This MAPK stimulatory activity could be specifically blocked by the epidermal growth factor receptor (EGFR) inhibitors, PD153035 and PD158780.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	epidermal growth factor receptor	Mus musculus	102-106
9856822-4	1998	CaN19 was strongly induced after 24 h of organ culture, and its induction could be blocked by PD153035, a specific inhibitor of EGF receptor tyrosine kinase activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	94-102	S100 calcium binding protein A2	Homo sapiens	0-5
9856822-4	1998	CaN19 was strongly induced after 24 h of organ culture, and its induction could be blocked by PD153035, a specific inhibitor of EGF receptor tyrosine kinase activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	94-102	epidermal growth factor receptor	Homo sapiens	128-140
9774435-8	1998	Stable transfection of EGFR-negative NR6 and EGFR-positive Swiss3T3 cells with oncogenic (G12V)Ha-Ras demonstrated that only the Ha-Ras-transfected Swiss 3T3 cells possessed constitutive MAPK activity, and this activity was sensitive to PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	237-245	Harvey rat sarcoma virus oncogene	Mus musculus	129-135
9815602-0	1997	PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	48-80
9664130-4	1998	Using the EGFR-overexpressing head and neck carcinoma cell line HN5, we have compared the biological consequences of treatment with an inhibitor of EGFR tyrosine kinase (PD153035) with anti-EGFR monoclonal antibodies (mAbs) ICR63 or ICR80.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	170-178	epidermal growth factor receptor	Homo sapiens	148-152
9664130-4	1998	Using the EGFR-overexpressing head and neck carcinoma cell line HN5, we have compared the biological consequences of treatment with an inhibitor of EGFR tyrosine kinase (PD153035) with anti-EGFR monoclonal antibodies (mAbs) ICR63 or ICR80.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	170-178	epidermal growth factor receptor	Homo sapiens	148-152
9558281-3	1998	We therefore examined the effects of a selective EGFR tyrosine kinase inhibitor, PD 153035, on proliferation and survival of five colon cancer cell lines whose autonomous proliferation is either EGFR ligand dependent or EGFR ligand independent.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	81-90	epidermal growth factor receptor	Homo sapiens	49-53
9580112-3	1998	Here we report that human keratinocytes undergo apoptosis when incubated with the blocking EGFR monoclonal antibody 225 IgG, or PD153035, a highly specific EGFR tyrosine kinase inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	128-136	epidermal growth factor receptor	Homo sapiens	156-160
9558281-8	1998	CONCLUSIONS: The EGFR tyrosine kinase inhibitor PD 153035 induces cytostasis and caspase-dependent apoptosis in EGFR ligand-dependent colon cancer cell lines.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	48-57	epidermal growth factor receptor	Homo sapiens	17-21
9558281-8	1998	CONCLUSIONS: The EGFR tyrosine kinase inhibitor PD 153035 induces cytostasis and caspase-dependent apoptosis in EGFR ligand-dependent colon cancer cell lines.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	48-57	epidermal growth factor receptor	Homo sapiens	112-116
9462709-5	1998	Both increased as well as reduced EGF-dependent adhesion could be blocked using either ligand-blocking monoclonal antibody 14E1 or the potent EGFR tyrosine kinase inhibitor PD 153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	173-182	epidermal growth factor receptor	Homo sapiens	142-146
9406816-3	1997	We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	227-236	epidermal growth factor receptor	Homo sapiens	79-111
9406816-3	1997	We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	227-236	epidermal growth factor receptor	Homo sapiens	113-117
9406816-3	1997	We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	227-236	epidermal growth factor receptor	Homo sapiens	121-126
9406816-3	1997	We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	227-236	epidermal growth factor receptor	Homo sapiens	173-178
9815602-1	1997	PD153035 is reported to be a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase and, to a lesser degree, of the closely related HER2/neu receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	66-104
9815602-1	1997	PD153035 is reported to be a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase and, to a lesser degree, of the closely related HER2/neu receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-186
9815602-2	1997	We show that PD153035 inhibits EGF-dependent EGF receptor phosphorylation and suppresses the proliferation and clonogenicity of a wide panel of EGF receptor-overexpressing human cancer cell lines.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	13-21	epidermal growth factor	Homo sapiens	31-34
9815602-2	1997	We show that PD153035 inhibits EGF-dependent EGF receptor phosphorylation and suppresses the proliferation and clonogenicity of a wide panel of EGF receptor-overexpressing human cancer cell lines.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	13-21	epidermal growth factor	Homo sapiens	45-48
9815602-2	1997	We show that PD153035 inhibits EGF-dependent EGF receptor phosphorylation and suppresses the proliferation and clonogenicity of a wide panel of EGF receptor-overexpressing human cancer cell lines.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	13-21	epidermal growth factor	Homo sapiens	45-48
9815602-3	1997	EGF receptor autophosphorylation in response to exogenous EGF was completely inhibited at PD153035 concentrations of >75 nM in cells overexpressing the EGF receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	90-98	epidermal growth factor	Homo sapiens	0-3
9815602-3	1997	EGF receptor autophosphorylation in response to exogenous EGF was completely inhibited at PD153035 concentrations of >75 nM in cells overexpressing the EGF receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	90-98	epidermal growth factor	Homo sapiens	58-61
9815602-3	1997	EGF receptor autophosphorylation in response to exogenous EGF was completely inhibited at PD153035 concentrations of >75 nM in cells overexpressing the EGF receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	90-98	epidermal growth factor	Homo sapiens	58-61
9815602-4	1997	In contrast, PD153035 only reduced heregulin-dependent tyrosine phosphorylation in HER2/neu-overexpressing cell lines at significantly higher concentrations (1400-2800 nM).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	13-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
9815602-6	1997	PD153035 caused a dose-dependent growth inhibition of EGF receptor-overexpressing cell lines at low micromolar concentrations, and the IC50 in monolayer cultures was less than 1 microM in most cell lines tested.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor	Homo sapiens	54-57
9815602-8	1997	In colony-forming assays, the PD153035 growth-inhibitory activity in cultures driven by endogenous (autocrine) ligand was correlated with EGF receptor number, with higher activity in cells expressing higher numbers of EGF receptors and only minimal activity in cells expressing normal numbers of EGF receptors but high HER2/neu levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	epidermal growth factor	Homo sapiens	138-141
9815602-8	1997	In colony-forming assays, the PD153035 growth-inhibitory activity in cultures driven by endogenous (autocrine) ligand was correlated with EGF receptor number, with higher activity in cells expressing higher numbers of EGF receptors and only minimal activity in cells expressing normal numbers of EGF receptors but high HER2/neu levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	epidermal growth factor	Homo sapiens	218-221
9815602-8	1997	In colony-forming assays, the PD153035 growth-inhibitory activity in cultures driven by endogenous (autocrine) ligand was correlated with EGF receptor number, with higher activity in cells expressing higher numbers of EGF receptors and only minimal activity in cells expressing normal numbers of EGF receptors but high HER2/neu levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	epidermal growth factor	Homo sapiens	218-221
9815602-8	1997	In colony-forming assays, the PD153035 growth-inhibitory activity in cultures driven by endogenous (autocrine) ligand was correlated with EGF receptor number, with higher activity in cells expressing higher numbers of EGF receptors and only minimal activity in cells expressing normal numbers of EGF receptors but high HER2/neu levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	30-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	319-323
9815602-10	1997	Cotreatment with C225, an anti-EGF receptor-blocking monoclonal antibody, further enhanced the antitumor activity of PD153035, suggesting mechanisms of action for C225 other than competition with ligand binding.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	117-125	epidermal growth factor	Homo sapiens	31-34
9228072-13	1997	A selective EGFR tyrosine kinase inhibitor PD153035 attenuated the Ras-, but not Src-, transformed phenotype.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	43-51	epidermal growth factor receptor	Rattus norvegicus	12-16
9276746-6	1997	The highly EGF receptor-specific tyrosine kinase inhibitor PD153035 strongly inhibited induction of all four transcripts in organ culture, as well as release of immunoreactive HB-EGF into the medium.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	59-67	epidermal growth factor receptor	Homo sapiens	11-23
8980296-6	1997	TGF-alpha stimulation of S6 kinase activity was inhibited in a concentration-dependent manner by rapamycin (IC50 < 0.2 nM) and the specific EGF receptor antagonist PD153035 (IC50 = 20 nM).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	167-175	transforming growth factor alpha	Homo sapiens	0-9
9223591-8	1997	In contrast, in the LM preparation, EGF-induced contractions were attentuated by the EGF receptor-kinase inhibitor, PD153035; the MAP-kinase-kinase (MEK) inhibitor, PD98059; the kinase C inhibitor, GF109203X; and the phosphatidylinositol 3"-kinase inhibitors, Wortmannin and LY294002; whereas ethanol-induced contractions were unaffected by these inhibitors.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	116-124	pro-epidermal growth factor	Cavia porcellus	36-39
9223591-8	1997	In contrast, in the LM preparation, EGF-induced contractions were attentuated by the EGF receptor-kinase inhibitor, PD153035; the MAP-kinase-kinase (MEK) inhibitor, PD98059; the kinase C inhibitor, GF109203X; and the phosphatidylinositol 3"-kinase inhibitors, Wortmannin and LY294002; whereas ethanol-induced contractions were unaffected by these inhibitors.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	116-124	pro-epidermal growth factor	Cavia porcellus	85-88
9010919-4	1997	The actions of ethanol were distinct from those of EGF in that EGF-induced contractions were sensitive to the kinase C inhibitor GF109203X, and the EGF receptor kinase inhibitor PD153035, whereas ethanol-induced contractions were refractory to these inhibitors.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	178-186	pro-epidermal growth factor	Cavia porcellus	63-66
9010919-4	1997	The actions of ethanol were distinct from those of EGF in that EGF-induced contractions were sensitive to the kinase C inhibitor GF109203X, and the EGF receptor kinase inhibitor PD153035, whereas ethanol-induced contractions were refractory to these inhibitors.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	178-186	pro-epidermal growth factor	Cavia porcellus	63-66
32950581-7	2020	Interestingly, as for winter crab at the same vitellogenic stage, the expression of SpVgR and SpCyclin B in ovary explants did not show significant increase until treated with higher concentration of 10 nM hEGF and longer incubation time of 12 h. In addition, the hEGF-induced effect could be suppressed by pre-treated with EGFR inhibitor AG1478 and PD153035, respectively, which further indicated that EGF-EGFR pathway played a vital role in ovarian development in mud crab.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	350-358	epidermal growth factor	Homo sapiens	206-210
8824347-1	1996	PD153035 is a potent (Ki = 6 pm) and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase that suppresses tyrosine phosphorylation of the EGF receptor in A431 cells at nanomolar concentrations in cell culture.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	63-101
8824347-1	1996	PD153035 is a potent (Ki = 6 pm) and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase that suppresses tyrosine phosphorylation of the EGF receptor in A431 cells at nanomolar concentrations in cell culture.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	166-178
8066447-1	1994	A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	24-33	epidermal growth factor receptor	Homo sapiens	48-86
34511032-9	2022	The EGFR tyrosine kinase inhibitor (PD153035), broad-spectrum matrix metalloproteinase inhibitor (GM6001) and Src tyrosine kinase inhibitor (PP2) inhibited PAR2-induced wound healing.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	36-44	coagulation factor II (thrombin) receptor-like 1	Mus musculus	156-160
34885111-7	2021	Treatment with PD153035, an EGFR inhibitor, revealed altered CRC expression of PD-L1 but only in gels lacking MSCs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	15-23	epidermal growth factor receptor	Homo sapiens	28-32
34885111-7	2021	Treatment with PD153035, an EGFR inhibitor, revealed altered CRC expression of PD-L1 but only in gels lacking MSCs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	15-23	CD274 molecule	Homo sapiens	79-84
35203275-5	2022	While the same phenomenon is also triggered by single molecular interactions between epidermal growth factor (EGF) and its receptor EGFR, pharmacological studies with cetuximab, PD153035, and caffeine suggest EGF signaling crosstalk to DNA damaging response to mediate rapid mitochondrial fission as a result of nNIR irradiation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	178-186	epidermal growth factor	Homo sapiens	85-108
35203275-5	2022	While the same phenomenon is also triggered by single molecular interactions between epidermal growth factor (EGF) and its receptor EGFR, pharmacological studies with cetuximab, PD153035, and caffeine suggest EGF signaling crosstalk to DNA damaging response to mediate rapid mitochondrial fission as a result of nNIR irradiation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	178-186	epidermal growth factor	Homo sapiens	110-113
35203275-5	2022	While the same phenomenon is also triggered by single molecular interactions between epidermal growth factor (EGF) and its receptor EGFR, pharmacological studies with cetuximab, PD153035, and caffeine suggest EGF signaling crosstalk to DNA damaging response to mediate rapid mitochondrial fission as a result of nNIR irradiation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	178-186	epidermal growth factor	Homo sapiens	209-212
32236267-7	2021	More importantly, compared with a standard EGFR-TKI, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), F-MPG and OH-MPG showed stronger tumor inhibition in preclinical models.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	98-106	epidermal growth factor receptor	Homo sapiens	43-47
32236267-9	2021	Ex vivo experiments showed that the levels of serum biomarkers and pathological changes in the liver were significantly reduced in the F-MPG and OH-MPG group, compared to PD153035 treated group.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	171-179	N-methylpurine DNA glycosylase	Homo sapiens	137-140
32236267-9	2021	Ex vivo experiments showed that the levels of serum biomarkers and pathological changes in the liver were significantly reduced in the F-MPG and OH-MPG group, compared to PD153035 treated group.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	171-179	N-methylpurine DNA glycosylase	Homo sapiens	148-151
32950581-7	2020	Interestingly, as for winter crab at the same vitellogenic stage, the expression of SpVgR and SpCyclin B in ovary explants did not show significant increase until treated with higher concentration of 10 nM hEGF and longer incubation time of 12 h. In addition, the hEGF-induced effect could be suppressed by pre-treated with EGFR inhibitor AG1478 and PD153035, respectively, which further indicated that EGF-EGFR pathway played a vital role in ovarian development in mud crab.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	350-358	epidermal growth factor	Homo sapiens	207-210
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	epidermal growth factor receptor	Homo sapiens	85-117
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	epidermal growth factor receptor	Homo sapiens	119-123
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	epidermal growth factor receptor	Homo sapiens	147-151
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	C-C motif chemokine ligand 20	Homo sapiens	198-203
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	mitogen-activated protein kinase 1	Homo sapiens	223-258
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	mitogen-activated protein kinase 1	Homo sapiens	260-263
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	mitogen-activated protein kinase 8	Homo sapiens	302-325
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	mitogen-activated protein kinase 8	Homo sapiens	327-330
31936670-4	2020	In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	162-170	mitogen-activated protein kinase 14	Homo sapiens	346-382
31313024-8	2019	Further, LV-antagomiR-7-induced osteoblast cytoprotection against Dex was abolished by the EGFR inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	118-126	epidermal growth factor receptor	Mus musculus	91-95
30735525-5	2019	Here, we investigated whether inhibiting EGFR using the EGFR tyrosine kinase inhibitor (TKI) PD153035 improves NAFLD.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	93-101	epidermal growth factor receptor	Mus musculus	41-45
31201806-9	2019	Inhibition of EGFR-signaling with PD153035 blocked the EMT response induced by co-treatment with EGF and TGFbeta2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	34-42	epidermal growth factor receptor	Rattus norvegicus	14-18
31201806-9	2019	Inhibition of EGFR-signaling with PD153035 blocked the EMT response induced by co-treatment with EGF and TGFbeta2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	34-42	transforming growth factor, beta 2	Rattus norvegicus	105-113
31324820-5	2019	Terminal differentiation, characterized by the increased expression of uroplakins, CK13, and CK20, was induced with the combination of Troglitazone + PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	150-158	keratin 13	Homo sapiens	83-87
31324820-5	2019	Terminal differentiation, characterized by the increased expression of uroplakins, CK13, and CK20, was induced with the combination of Troglitazone + PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	150-158	keratin 20	Homo sapiens	93-97
30735525-7	2019	Inhibiting EGFR using PD153035 significantly reduced phosphatidylinositol-3-kinase/protein kinase B signaling and sterol responsive elementary binding protein 1 and 2 expression, which prevented HFD-induced hepatic steatosis and hypercholesterolemia by reducing de novo lipogenesis and cholesterol synthesis and enhancing fatty acid oxidation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	22-30	epidermal growth factor receptor	Mus musculus	11-15
29751044-4	2018	Interestingly, overexpression of EGFR or treatment with EGF decreases miR-200c expression and this is reversed after treatment with EGFR specific kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	163-171	epidermal growth factor receptor	Homo sapiens	33-37
30290164-7	2019	Pharmacologic inhibition of EGFR-signaling using PD153035 inhibited TGFbeta-induced EMT, including the upregulation of mesenchymal markers and downregulation of epithelial markers.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	49-57	epidermal growth factor receptor	Homo sapiens	28-32
30290164-7	2019	Pharmacologic inhibition of EGFR-signaling using PD153035 inhibited TGFbeta-induced EMT, including the upregulation of mesenchymal markers and downregulation of epithelial markers.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	49-57	transforming growth factor beta 1	Homo sapiens	68-75
29751044-4	2018	Interestingly, overexpression of EGFR or treatment with EGF decreases miR-200c expression and this is reversed after treatment with EGFR specific kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	163-171	microRNA 200c	Homo sapiens	70-78
29751044-4	2018	Interestingly, overexpression of EGFR or treatment with EGF decreases miR-200c expression and this is reversed after treatment with EGFR specific kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	163-171	epidermal growth factor receptor	Homo sapiens	132-136
27436370-7	2017	PD153035 (EGFR inhibitor) and U0126 (ERK inhibitor) inhibited AQP3 expression and also the attachment and outgrowth of blastocysts.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Mus musculus	10-14
29518481-0	2018	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	50-58	epidermal growth factor receptor	Homo sapiens	0-32
29518481-0	2018	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	50-58	epidermal growth factor receptor	Homo sapiens	34-38
29518481-0	2018	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	50-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	68-73
29518481-2	2018	In this study, we conducted in vitro and in vivo experiments to determine whether PD153035, an inhibitor of EGFR, could reverse ABCG2-mediated MDR in human NSCLC and transfected cells overexpressing ABCG2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	epidermal growth factor receptor	Homo sapiens	108-112
29518481-2	2018	In this study, we conducted in vitro and in vivo experiments to determine whether PD153035, an inhibitor of EGFR, could reverse ABCG2-mediated MDR in human NSCLC and transfected cells overexpressing ABCG2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	128-133
29518481-2	2018	In this study, we conducted in vitro and in vivo experiments to determine whether PD153035, an inhibitor of EGFR, could reverse ABCG2-mediated MDR in human NSCLC and transfected cells overexpressing ABCG2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	82-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	199-204
29518481-3	2018	The efficacy of SN-38, topotecan, and mitoxantrone (MX) were significantly increased by PD153035, PD153035 significantly reversed ABCG2-mediated MDR by attenuating the efflux activity of this transporter.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	88-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	130-135
29518481-3	2018	The efficacy of SN-38, topotecan, and mitoxantrone (MX) were significantly increased by PD153035, PD153035 significantly reversed ABCG2-mediated MDR by attenuating the efflux activity of this transporter.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	98-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	130-135
29518481-4	2018	In addition, PD153035 significantly down-regulated the expression of the ABCG2 transporter protein.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	13-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-78
29518481-6	2018	These results, provided that they can be extrapolated to humans, suggest that the combination of topotecan and PD153035 could be a promising therapeutic strategy to attenuate the resistance to topotecan, as well as other anticancer drugs, mediated by the overexpression of ABCG2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	111-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	273-278
27436370-7	2017	PD153035 (EGFR inhibitor) and U0126 (ERK inhibitor) inhibited AQP3 expression and also the attachment and outgrowth of blastocysts.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	aquaporin 3	Mus musculus	62-66
26464147-12	2016	Administration of PD153035 resulted in a significantly reduced lung inflammation as well as EGFR phosphorylation induced by O3 exposure.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	18-26	epidermal growth factor receptor	Mus musculus	92-96
27220321-7	2016	Additionally, pre-treatment with either EGFR kinase inhibitor PD153035 or ERK1/2 kinase inhibitor PD98059 in HCT116/5-FU cells partly inhibits P-glycoprotein expression and AP-1 binding activity (P < 0.05).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	62-70	epidermal growth factor receptor	Homo sapiens	40-44
26464147-7	2016	BALB/c mice were intratracheally instilled with the EGFR kinase inhibitor PD153035 2 h prior to O3 exposure and every other day thereafter.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor receptor	Mus musculus	52-56
27220321-7	2016	Additionally, pre-treatment with either EGFR kinase inhibitor PD153035 or ERK1/2 kinase inhibitor PD98059 in HCT116/5-FU cells partly inhibits P-glycoprotein expression and AP-1 binding activity (P < 0.05).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	62-70	ATP binding cassette subfamily B member 1	Homo sapiens	143-157
27220321-7	2016	Additionally, pre-treatment with either EGFR kinase inhibitor PD153035 or ERK1/2 kinase inhibitor PD98059 in HCT116/5-FU cells partly inhibits P-glycoprotein expression and AP-1 binding activity (P < 0.05).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	62-70	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-177
26986216-6	2016	Blocking the EGFR/MAPK pathway by its specific inhibitor PD153035 or EGFR small interfering RNA (siRNA) resulted in the reduced MDR of K562/ADR cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	57-65	epidermal growth factor receptor	Homo sapiens	13-17
27121290-4	2016	Decreased levels of glucose and oxygen led to resistance against the EGFR inhibitor PD153035, whereas high glucose amounts and normoxia sensitised glioma cells towards the inhibitor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	84-92	epidermal growth factor	Homo sapiens	69-73
27121290-6	2016	2DG, an inhibitor of glycolysis, and the AMPK activator A769662 reduced glucose consumption, induced phosphorylation of AMPK and mimicked the effects of low glucose availability on the toxicity of PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	197-205	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	41-45
25482018-11	2015	Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	130-138	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	32-36
26334931-0	2016	Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	29-37	epidermal growth factor receptor	Homo sapiens	54-58
26334931-6	2016	HCC827 and PC9 cells, which were highly sensitive to EGFR-TKIs, exhibited higher (11)C-PD153035 uptakes than the other cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	proprotein convertase subtilisin/kexin type 9	Homo sapiens	11-14
26334931-6	2016	HCC827 and PC9 cells, which were highly sensitive to EGFR-TKIs, exhibited higher (11)C-PD153035 uptakes than the other cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	epidermal growth factor receptor	Homo sapiens	53-57
26334931-12	2016	In conclusion, (11)C-PD153035 can serve as an EGFR imaging agent in vitro and in vivo, and predicts sensitivity to EGFR-TKIs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	21-29	epidermal growth factor receptor	Homo sapiens	46-50
26334931-12	2016	In conclusion, (11)C-PD153035 can serve as an EGFR imaging agent in vitro and in vivo, and predicts sensitivity to EGFR-TKIs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	21-29	epidermal growth factor receptor	Homo sapiens	115-119
24639330-8	2015	Pretreatment with EGFR inhibitors AG1478 and PD153035 significantly limited Pb(2+) -induced reduction in DNMT3a mRNA.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	45-53	epidermal growth factor receptor	Homo sapiens	18-22
24639330-8	2015	Pretreatment with EGFR inhibitors AG1478 and PD153035 significantly limited Pb(2+) -induced reduction in DNMT3a mRNA.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	45-53	DNA methyltransferase 3 alpha	Homo sapiens	105-111
25482018-11	2015	Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	130-138	epidermal growth factor receptor	Homo sapiens	80-112
25482018-11	2015	Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	130-138	epidermal growth factor receptor	Homo sapiens	114-118
25482018-11	2015	Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	130-138	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	174-178
25482018-11	2015	Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	130-138	epidermal growth factor receptor	Homo sapiens	182-186
25803810-6	2015	The NEU3-mediated activation was largely abrogated by the EGFR inhibitor AG1478 or PD153035, but significant clonogenic growth still remained.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	83-91	neuraminidase 3	Homo sapiens	4-8
25834353-6	2015	RESULTS: TNF-alpha- and IFN-gamma-induced CCL22 production was inhibited by PD98059, PD153035, Bay 11-7085, SB202190, c-Jun N-terminal kinase (JNK) inhibitor II, and Janus kinase (JAK) inhibitor 1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	85-93	tumor necrosis factor	Homo sapiens	9-18
25834353-6	2015	RESULTS: TNF-alpha- and IFN-gamma-induced CCL22 production was inhibited by PD98059, PD153035, Bay 11-7085, SB202190, c-Jun N-terminal kinase (JNK) inhibitor II, and Janus kinase (JAK) inhibitor 1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	85-93	interferon gamma	Homo sapiens	24-33
25834353-6	2015	RESULTS: TNF-alpha- and IFN-gamma-induced CCL22 production was inhibited by PD98059, PD153035, Bay 11-7085, SB202190, c-Jun N-terminal kinase (JNK) inhibitor II, and Janus kinase (JAK) inhibitor 1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	85-93	C-C motif chemokine ligand 22	Homo sapiens	42-47
24106166-6	2015	Upregulation of the IL-8 gene was abrogated by the MEK inhibitor, PD98059, and partially suppressed by the epidermal growth factor receptor inhibitors, AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	163-171	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
23765435-8	2015	Epidermal growth factor receptor (EGFR) inhibitors AG1478 and PD153035 reduced both transcription and phosphorylation by extracellular signal-regulated kinase (ERK1/2).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	62-70	epidermal growth factor receptor	Homo sapiens	0-32
23765435-8	2015	Epidermal growth factor receptor (EGFR) inhibitors AG1478 and PD153035 reduced both transcription and phosphorylation by extracellular signal-regulated kinase (ERK1/2).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	62-70	epidermal growth factor receptor	Homo sapiens	34-38
23765435-8	2015	Epidermal growth factor receptor (EGFR) inhibitors AG1478 and PD153035 reduced both transcription and phosphorylation by extracellular signal-regulated kinase (ERK1/2).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	62-70	mitogen-activated protein kinase 3	Homo sapiens	160-166
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	26-34	epidermal growth factor receptor	Homo sapiens	3-7
25550802-7	2014	The EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	27-35	epidermal growth factor receptor	Homo sapiens	4-8
25550802-7	2014	The EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	27-35	epidermal growth factor	Homo sapiens	4-7
25550802-7	2014	The EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	27-35	aquaporin 8	Homo sapiens	57-61
25329617-7	2014	We discovered that epidermal growth factor receptor (EGFR) trans-activation mediated FLZ-induced AKT activation and the pro-survival effect in RPE cells, and the anti-apoptosis effect of FLZ against H2O2 was inhibited by the EGFR inhibitor, PD153035, or by EGFR shRNA-knockdown.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	241-249	epidermal growth factor receptor	Homo sapiens	19-51
25329617-7	2014	We discovered that epidermal growth factor receptor (EGFR) trans-activation mediated FLZ-induced AKT activation and the pro-survival effect in RPE cells, and the anti-apoptosis effect of FLZ against H2O2 was inhibited by the EGFR inhibitor, PD153035, or by EGFR shRNA-knockdown.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	241-249	epidermal growth factor receptor	Homo sapiens	53-57
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	26-34	epidermal growth factor	Homo sapiens	3-6
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	26-34	aquaporin 8	Homo sapiens	56-60
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	26-34	epidermal growth factor	Homo sapiens	44-47
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	epidermal growth factor receptor	Homo sapiens	3-7
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	epidermal growth factor	Homo sapiens	3-6
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	aquaporin 8	Homo sapiens	95-99
25124631-6	2014	An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	168-176	epidermal growth factor	Homo sapiens	44-47
24335566-0	2014	A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	68-76	epidermal growth factor receptor	Homo sapiens	17-21
24335566-7	2014	The SUVmax/WM (11C-PD153035 uptake in the white matter of the contralateral normal hemisphere) ratio was used to indicate the EGFR expression level in the ROI in PET/CT, and it was correlated with the EGFR expression detected by IHC and western blot analysis.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	19-27	epidermal growth factor receptor	Homo sapiens	126-130
24354805-6	2013	Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more sensitive to the EGFR-targeted TKIs lapatinib and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	140-148	annexin A6	Homo sapiens	54-59
24354805-6	2013	Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more sensitive to the EGFR-targeted TKIs lapatinib and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	140-148	epidermal growth factor receptor	Homo sapiens	107-111
23632456-5	2013	Intraventricular infusion of the ErbB1 inhibitors ZD1839 and PD153035 in these animals ameliorated the deficits in startle response and prepulse inhibition in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	61-69	epidermal growth factor receptor	Rattus norvegicus	33-38
24003078-0	2013	Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	68-76	epidermal growth factor receptor	Rattus norvegicus	14-46
24003078-2	2013	One of the most promising candidates is the (11)C-labeled analog of the EGFR tyrosine kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	103-111	epidermal growth factor receptor	Rattus norvegicus	72-76
22974583-5	2012	We further found that epidermal growth factor (EGF) receptor up-regulates Kaiso at the RNA and protein levels in prostate cancer cell lines, but more interestingly causes a shift of cytoplasmic Kaiso to the nucleus that is reversed by the EGF receptor-specific kinase inhibitor, PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	279-287	epidermal growth factor receptor	Homo sapiens	22-60
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	epidermal growth factor receptor	Bos taurus	117-121
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	prostaglandin-endoperoxide synthase 2	Bos taurus	238-243
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	prostaglandin E receptor 2	Bos taurus	245-251
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	TNF alpha induced protein 6	Bos taurus	253-260
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	progesterone receptor	Bos taurus	262-265
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	interstitial collagenase	Bos taurus	267-271
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	vascular endothelial growth factor A	Bos taurus	273-278
23178756-9	2013	Results from RT-PCR analyses revealed that EREG and AREG mRNAs were induced by forskolin treatment in vitro; but the EGFR inhibitor PD153035 suppressed the forskolin-dependent induction of several ovulation-related transcripts, including PTGS2, PTGER2, TNFAIP6, PGR, MMP1, VEGFA, and CTSL2 mRNAs.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	132-140	cathepsin L2	Bos taurus	284-289
22797910-8	2012	The EGFR tyrosine kinase inhibitor PD153035 reversed the elevated proliferation seen in the absence of SHP-1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	35-43	epidermal growth factor receptor	Homo sapiens	4-8
22797910-8	2012	The EGFR tyrosine kinase inhibitor PD153035 reversed the elevated proliferation seen in the absence of SHP-1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	35-43	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	103-108
22974583-5	2012	We further found that epidermal growth factor (EGF) receptor up-regulates Kaiso at the RNA and protein levels in prostate cancer cell lines, but more interestingly causes a shift of cytoplasmic Kaiso to the nucleus that is reversed by the EGF receptor-specific kinase inhibitor, PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	279-287	epidermal growth factor receptor	Homo sapiens	239-251
22866118-7	2011	Pre-treatment with the EGFR inhibitor PD153035 was found to markedly enhance ACC phosphorylation, whereas AMP-activated protein kinase (AMPK) activator AICAR was found to marginally enhance ACC phosphorylation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	38-46	epidermal growth factor receptor	Homo sapiens	23-27
22735833-7	2012	The activity of AQP3 and cell migration were inhibited by PD153035,             U0126 and CuSO4 (AQP3 water transport inhibitor).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	58-66	aquaporin 3 (Gill blood group)	Homo sapiens	16-20
22517768-8	2012	The EGFR tyrosine kinase inhibitor PD153035 also abolished 2fLI-induced COX-2 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	35-43	epidermal growth factor receptor	Homo sapiens	4-8
22517768-8	2012	The EGFR tyrosine kinase inhibitor PD153035 also abolished 2fLI-induced COX-2 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	35-43	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77
21903741-2	2011	This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	122-130	epidermal growth factor receptor	Homo sapiens	157-189
21903741-2	2011	This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	122-130	epidermal growth factor receptor	Homo sapiens	191-195
21903741-2	2011	This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	122-130	epidermal growth factor receptor	Homo sapiens	281-285
21435385-7	2011	NF-kappaB inhibitor BAY 11-7082 suppressed Pb2+-induced COX-2 mRNA expression, and EGFR inhibitors AG1478 and PD153035 as well as EGFR small interfering RNA reduced the coincident nuclear translocation of NF-kappaB.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	110-118	epidermal growth factor receptor	Homo sapiens	83-87
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor receptor	Homo sapiens	0-4
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	mitogen-activated protein kinase 1	Homo sapiens	9-12
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor	Homo sapiens	0-3
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor receptor	Homo sapiens	84-88
22694592-9	2012	EGFR inhibitor PD153035 suppressed regeneration of 50% grafts and largely abrogated stimulation of regeneration of 30% grafts by AR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	15-23	epidermal growth factor receptor	Mus musculus	0-4
22694592-9	2012	EGFR inhibitor PD153035 suppressed regeneration of 50% grafts and largely abrogated stimulation of regeneration of 30% grafts by AR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	15-23	amphiregulin	Mus musculus	129-131
22119079-6	2012	The anti-apoptotic effect is maintained in the presence of tyrosine kinase inhibitor genistein and the epidermal growth factor receptor inhibitor PD153035, but is suppressed by the PI3K inhibitor Ly294002 and the Akt inhibitor Akti-1/2.The unique PI3K regulatory subunit p55gamma was upregulated by berberine during ischemia-reperfusion and was not blocked by these inhibitors.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	146-154	epidermal growth factor receptor	Rattus norvegicus	103-135
21964676-9	2012	Similar results were obtained in DU-145 prostate cancer cells induced to re-express E-cadherin in hepatocyte coculture or following chemical induction by the GnRH agonist buserelin or the EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	203-211	epidermal growth factor receptor	Homo sapiens	188-192
22613406-3	2012	This study investigated the  therapeutic and preventive effects of an inhibitor of EGFR (PD153035) on OSCC.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	89-97	epidermal growth factor receptor	Homo sapiens	83-87
22613406-7	2012	PD153035 inhibited the DMBA-induced increases in cell proliferation and in levels of phosphorylated EGFR and phosphorylated signal transducer and activator of transcription  3 (STAT3) protein in the hamster cheek pouch.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	100-104
22613406-8	2012	CONCLUSIONS: Inhibitors of EGFR, such as PD153035, have potential value in the treatment and prevention of OSCC.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	41-49	epidermal growth factor receptor	Homo sapiens	27-31
22712848-7	2012	PD153035 (10 muM), an epidermal growth factor (EGF) receptor antagonist, attenuated the PM2.5-induced elevation in arginase activity and arginase II expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	22-60
21820892-11	2011	On the basis of the inhibitor concentration dependent electrochemical signal, the half-maximal inhibition value IC(50) of three EGFR inhibitors, PD-153035, OSI-774 and ZD-1839, and their corresponding inhibition constants K(i) were estimated, which were in agreement with those obtained from the conventional kinase assay.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	145-154	epidermal growth factor receptor	Homo sapiens	128-132
20596631-8	2010	The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-alpha protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	200-208	gastrin releasing peptide	Homo sapiens	14-17
21058048-1	2011	OBJECTIVE: A radioiodinated analog of PD153035 (m-IPQ) was evaluated as a potential epidermal growth factor receptor tyrosine kinase (EGFR-TK) activity imaging ligand for SPECT.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	38-46	epidermal growth factor receptor	Mus musculus	134-138
21058048-11	2011	The selectivity toward EGFR-TK of m-IPQ was confirmed by the pretreatment experiment with EGFR-TK specific inhibitors, PD153035, Genistein.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	119-127	epidermal growth factor receptor	Mus musculus	23-27
21130075-2	2011	Recently, PD153035, brominated anilinoquinazoline, has been reported to be not only a highly selective inhibitor of epidermal growth factor receptor but also a DNA intercalator.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	10-18	epidermal growth factor receptor	Homo sapiens	116-148
20882990-6	2010	We further showed that the secretory changes of APP and cystatin C in CNE-2 after TGF-alpha stimulation could be abrogated by pretreatment of EGFR tyrosine kinase inhibitor PD153035 and PI3 kinase inhibitor Wortmannin, validating that APP and cystatin C are EGFR-regulated secreted proteins in NPC cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	173-181	cystatin C	Homo sapiens	56-66
20882990-6	2010	We further showed that the secretory changes of APP and cystatin C in CNE-2 after TGF-alpha stimulation could be abrogated by pretreatment of EGFR tyrosine kinase inhibitor PD153035 and PI3 kinase inhibitor Wortmannin, validating that APP and cystatin C are EGFR-regulated secreted proteins in NPC cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	173-181	transforming growth factor alpha	Homo sapiens	82-91
20882990-6	2010	We further showed that the secretory changes of APP and cystatin C in CNE-2 after TGF-alpha stimulation could be abrogated by pretreatment of EGFR tyrosine kinase inhibitor PD153035 and PI3 kinase inhibitor Wortmannin, validating that APP and cystatin C are EGFR-regulated secreted proteins in NPC cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	173-181	epidermal growth factor receptor	Homo sapiens	142-146
20590818-5	2010	Further, PD153035, a gefitinib prototype, induced CCL2 and CCL5 mRNA and protein expression in HaCaT and HSC-1 keratinocyte cell lines with or without interleukin-1 (IL-1) treatment in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	C-C motif chemokine ligand 2	Homo sapiens	50-54
20590818-5	2010	Further, PD153035, a gefitinib prototype, induced CCL2 and CCL5 mRNA and protein expression in HaCaT and HSC-1 keratinocyte cell lines with or without interleukin-1 (IL-1) treatment in vitro.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	C-C motif chemokine ligand 5	Homo sapiens	59-63
20590818-6	2010	PD153035 also reduced the levels of interleukin-1 receptor 2 (IL-1R2), an IL-1 decoy receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	interleukin 1 receptor type 2	Homo sapiens	36-60
20590818-6	2010	PD153035 also reduced the levels of interleukin-1 receptor 2 (IL-1R2), an IL-1 decoy receptor.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	interleukin 1 receptor type 2	Homo sapiens	62-68
21472131-8	2011	Treatment of KMBC cells with rhTFF2 stimulated proliferation, triggered phosphorylation of EGFR and downstream extracellular signal related kinase (ERK), whereas co-incubation with the EGFR tyrosine kinase inhibitor, PD153035, blocked rhTFF2-dependent proliferation and EGFR/ERK responses.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	217-225	epidermal growth factor receptor	Homo sapiens	185-189
21472131-8	2011	Treatment of KMBC cells with rhTFF2 stimulated proliferation, triggered phosphorylation of EGFR and downstream extracellular signal related kinase (ERK), whereas co-incubation with the EGFR tyrosine kinase inhibitor, PD153035, blocked rhTFF2-dependent proliferation and EGFR/ERK responses.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	217-225	epidermal growth factor receptor	Homo sapiens	185-189
20538380-3	2010	This work describes the synthesis and initial tumor affinity testing of the EGFR antagonist (123)I-mAb425 and the EGF receptor tyrosine kinase (EGFR-TK) inhibitor (123)I-PD153035 as potential imaging probes for studying EGFR-expressing prostate cancer using single photon emission tomography.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	170-178	epidermal growth factor receptor	Homo sapiens	144-148
20538380-3	2010	This work describes the synthesis and initial tumor affinity testing of the EGFR antagonist (123)I-mAb425 and the EGF receptor tyrosine kinase (EGFR-TK) inhibitor (123)I-PD153035 as potential imaging probes for studying EGFR-expressing prostate cancer using single photon emission tomography.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	170-178	epidermal growth factor receptor	Homo sapiens	144-148
20538380-4	2010	METHODS: (123)I-mAb425 and (123)I-PD153035 were prepared, starting from the IgG2a antibody and EGFR antagonist mAb425, that binds to the external domain of the EGF receptors, and from the EGFR-TK inhibitor PD153035, targeting the intra-endothelial tyrosine kinase domain of the EGFR, respectively.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	34-42	epidermal growth factor receptor	Homo sapiens	95-99
20596631-8	2010	The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-alpha protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	200-208	mitogen-activated protein kinase 3	Homo sapiens	21-27
19804359-6	2009	These downstream phosphorylation events can be inhibited by treatment with the EGFR kinase inhibitor PD 153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	101-110	epidermal growth factor receptor	Homo sapiens	79-83
20641571-13	2004	A novel small molecule, 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), has been reported to be a potent tyrosine kinase inhibitor preventing EGFR activation and thus inhibiting proliferation of cancer cells (14).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	71-79	epidermal growth factor receptor	Homo sapiens	152-156
19376214-7	2009	Furthermore, NaF-induced COX-2 expression was markedly suppressed by the Src family kinase (SFK) inhibitor PP2, but only partially suppressed by the epidermal growth factor receptor (EGFR) inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	199-207	C-X-C motif chemokine ligand 8	Homo sapiens	13-16
19376214-7	2009	Furthermore, NaF-induced COX-2 expression was markedly suppressed by the Src family kinase (SFK) inhibitor PP2, but only partially suppressed by the epidermal growth factor receptor (EGFR) inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	199-207	epidermal growth factor receptor	Homo sapiens	149-181
19376214-7	2009	Furthermore, NaF-induced COX-2 expression was markedly suppressed by the Src family kinase (SFK) inhibitor PP2, but only partially suppressed by the epidermal growth factor receptor (EGFR) inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	199-207	epidermal growth factor receptor	Homo sapiens	183-187
19696185-0	2009	EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Mus musculus	0-4
19696185-4	2009	We investigated, herein, in vivo efficacy and associated molecular mechanisms by which PD153035, an EGFR tyrosine kinase inhibitor, improved diabetes control and insulin action.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	epidermal growth factor receptor	Mus musculus	100-104
19696185-6	2009	RESULTS: PD153035 treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	tumor necrosis factor	Mus musculus	107-140
19696185-6	2009	RESULTS: PD153035 treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	interleukin 6	Mus musculus	146-164
19696185-6	2009	RESULTS: PD153035 treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	tumor necrosis factor	Mus musculus	335-344
19696185-6	2009	RESULTS: PD153035 treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	interleukin 6	Mus musculus	349-353
20641571-14	2004	PD153035 reversibly binds to the inner membrane ATP-binding domain on EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	70-74
20641571-15	2004	[(11)C]PD153035 has been evaluated in vivo as a positron emission tomography (PET) agent to measure EGFR expression in tumors.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	7-15	epidermal growth factor receptor	Homo sapiens	100-104
18831963-5	2008	An inhibitor of the tyrosine kinase activity of the EGF receptor, PD153035, blocked the EGF-induced up-regulation of both Sema3A mRNA and protein in corneal fibroblasts.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	66-74	epidermal growth factor	Homo sapiens	52-55
19133285-7	2009	Specific pharmacological inhibitors, PD153035 for epidermal growth factor receptor (EGFR) and SU6656 for Src family tyrosine kinases (SFK), but not AG1296 for platelet-derived growth factor receptor, could suppress the Pb-induced tyrosine kinases, PKCalpha, Ras-GTP, phospho-Raf-1(S338) and phospho-ERK1/2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	37-45	epidermal growth factor receptor	Homo sapiens	50-82
19133285-7	2009	Specific pharmacological inhibitors, PD153035 for epidermal growth factor receptor (EGFR) and SU6656 for Src family tyrosine kinases (SFK), but not AG1296 for platelet-derived growth factor receptor, could suppress the Pb-induced tyrosine kinases, PKCalpha, Ras-GTP, phospho-Raf-1(S338) and phospho-ERK1/2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	37-45	epidermal growth factor receptor	Homo sapiens	84-88
18802922-3	2008	Treatment of confluent HGE-17 cells with the phosphatidylinositol 3-kinase inhibitor, LY294002, and the epidermal growth factor receptor inhibitor, PD153035, strongly reduced basal and TGFalpha-stimulated cell spreading.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	148-156	epidermal growth factor receptor	Homo sapiens	104-136
18831963-5	2008	An inhibitor of the tyrosine kinase activity of the EGF receptor, PD153035, blocked the EGF-induced up-regulation of both Sema3A mRNA and protein in corneal fibroblasts.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	66-74	epidermal growth factor	Homo sapiens	88-91
18831963-5	2008	An inhibitor of the tyrosine kinase activity of the EGF receptor, PD153035, blocked the EGF-induced up-regulation of both Sema3A mRNA and protein in corneal fibroblasts.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	66-74	semaphorin 3A	Homo sapiens	122-128
18346929-11	2008	Inhibition of epidermal growth factor receptor activation by PD153035 blocked extracellular signal-regulated kinase phosphorylation and restored Abeta1-40 levels.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	61-69	epidermal growth factor receptor	Homo sapiens	14-46
19069650-6	2008	Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	epidermal growth factor receptor	Homo sapiens	39-43
19069650-6	2008	Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	intercellular adhesion molecule 1	Homo sapiens	138-144
19069650-6	2008	Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	epidermal growth factor receptor	Homo sapiens	213-217
19069650-6	2008	Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	AKT serine/threonine kinase 1	Homo sapiens	231-234
19069650-6	2008	Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	54-62	intercellular adhesion molecule 1	Homo sapiens	289-295
18400375-5	2008	EGFR tyrosine kinase inhibitors, such as PD153035, AG1478, as well as non-specific tyrosine kinase inhibitor PP2 cannot reverse EGF-induced down-regulation of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	41-49	epidermal growth factor receptor	Homo sapiens	0-4
18400375-5	2008	EGFR tyrosine kinase inhibitors, such as PD153035, AG1478, as well as non-specific tyrosine kinase inhibitor PP2 cannot reverse EGF-induced down-regulation of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	41-49	TXK tyrosine kinase	Homo sapiens	5-20
18400375-5	2008	EGFR tyrosine kinase inhibitors, such as PD153035, AG1478, as well as non-specific tyrosine kinase inhibitor PP2 cannot reverse EGF-induced down-regulation of EGFR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	41-49	epidermal growth factor	Homo sapiens	0-3
18400375-6	2008	These findings thus permit us to develop the following exciting but unconventional strategy to sensitize cancer cells, namely, by priming ovarian cancer cells with EGF and EGFR inhibitor PD153035, before chemotherapy.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	187-195	epidermal growth factor receptor	Homo sapiens	172-176
18400375-9	2008	Further studies showed that PD153035, which does not reverse ligand-induced EGFR down-regulation, blocks EGF-induced EGFR activation as well as EGFR"s binding to c-cbl and Grb2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	epidermal growth factor receptor	Homo sapiens	117-121
18400375-9	2008	Further studies showed that PD153035, which does not reverse ligand-induced EGFR down-regulation, blocks EGF-induced EGFR activation as well as EGFR"s binding to c-cbl and Grb2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	epidermal growth factor receptor	Homo sapiens	117-121
18400375-9	2008	Further studies showed that PD153035, which does not reverse ligand-induced EGFR down-regulation, blocks EGF-induced EGFR activation as well as EGFR"s binding to c-cbl and Grb2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	Cbl proto-oncogene	Homo sapiens	162-167
18400375-9	2008	Further studies showed that PD153035, which does not reverse ligand-induced EGFR down-regulation, blocks EGF-induced EGFR activation as well as EGFR"s binding to c-cbl and Grb2.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	28-36	growth factor receptor bound protein 2	Homo sapiens	172-176
17882547-7	2008	Treatment of the EGFR positive lines with the EGFR inhibitor PD153035 and amphiregulin-neutralizing antibodies reduced PTHrP mRNA levels by 50-70%.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	61-69	epidermal growth factor receptor	Homo sapiens	17-21
17882547-7	2008	Treatment of the EGFR positive lines with the EGFR inhibitor PD153035 and amphiregulin-neutralizing antibodies reduced PTHrP mRNA levels by 50-70%.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	61-69	epidermal growth factor receptor	Homo sapiens	46-50
17882547-7	2008	Treatment of the EGFR positive lines with the EGFR inhibitor PD153035 and amphiregulin-neutralizing antibodies reduced PTHrP mRNA levels by 50-70%.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	61-69	parathyroid hormone like hormone	Homo sapiens	119-124
18636178-8	2008	PD153035, an EGFR inhibitor, and U0126, an ERK inhibitor, inhibit atRA-induced upregulation of AQP3.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Homo sapiens	13-17
18636178-8	2008	PD153035, an EGFR inhibitor, and U0126, an ERK inhibitor, inhibit atRA-induced upregulation of AQP3.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	aquaporin 3 (Gill blood group)	Homo sapiens	95-99
18398842-5	2008	These cellular responses were blocked by inhibiting the tyrosine kinase activity of EGFR with PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	94-102	epidermal growth factor receptor	Mus musculus	84-88
18953832-1	2008	OBJECTIVE: To investigate the value of 11C-PD153035 as an EGFR imaging agent in C6 tumor-bearing rat.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	43-51	epidermal growth factor receptor	Rattus norvegicus	58-62
18986098-5	2008	Leptin stimulated proliferation in four OAC lines expressing leptin receptors (OE33, OE19, BIC-1 and FLO) and this was abolished by specific EGFR inhibitors (PD153035 and AG1478).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	158-166	leptin	Homo sapiens	0-6
18986098-5	2008	Leptin stimulated proliferation in four OAC lines expressing leptin receptors (OE33, OE19, BIC-1 and FLO) and this was abolished by specific EGFR inhibitors (PD153035 and AG1478).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	158-166	epidermal growth factor receptor	Homo sapiens	141-145
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	epidermal growth factor receptor	Mus musculus	18-50
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	epidermal growth factor receptor	Mus musculus	52-56
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	thymoma viral proto-oncogene 1	Mus musculus	108-111
17608728-0	2007	The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	59-67	epidermal growth factor receptor	Homo sapiens	16-48
17608728-0	2007	The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	59-67	retinoic acid receptor beta	Homo sapiens	145-172
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	epidermal growth factor receptor	Homo sapiens	34-66
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	epidermal growth factor receptor	Homo sapiens	68-72
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	retinoic acid receptor beta	Homo sapiens	117-144
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	retinoic acid receptor beta	Homo sapiens	146-154
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	epidermal growth factor receptor	Homo sapiens	249-253
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	epidermal growth factor receptor	Homo sapiens	255-260
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	293-298
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	erb-b2 receptor tyrosine kinase 3	Homo sapiens	300-305
17608728-1	2007	We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4).	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	100-108	erb-b2 receptor tyrosine kinase 4	Homo sapiens	307-312
17608728-4	2007	Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	45-53	epidermal growth factor receptor	Homo sapiens	30-34
17608728-13	2007	These data further support the notion that induction of the RAR-beta tumor-suppressor gene in cancer cells by PD153035 is mediated at least in part by its DNA intercalating activity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	110-118	retinoic acid receptor beta	Homo sapiens	60-68